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Primary  open-angle  glaucoma  (POAG)  is  the  leading  cause  of  irreversible  blindness  
worldwide.  Intraocular  pressure  (IOP)  the  only  known  modifiable  risk  factor  for  this  disease. 
In  POAG,  elevated  IOP  leads  to  progressive  loss  of  retinal  ganglion  cells,  with  IOP  being  
primarily  modulated  by  trabecular  meshwork  cells  (TMCs)  in  the  iridocorneal  angle.  The  
precise  molecular  drivers  for  the  differentiation  or  dysfunction  of  TMCs  is  poorly  
understood.  A  number  of  transcription  factors  have  been  implicated  in  development  of  the  
ocular  anterior  segment,  and  recently  a  large  genome-wide  association  study  identified  53  
loci  associated  with  variation  in  IOP. 
Aim:  
The  overriding  aims  of  this  thesis  were: 
1.  To  determine  whether  dental  pulp-Mesenchymal  stem  cells  (DP-MSCs)  could  be  induced
to  exhibit  the  phenotypic  properties  of  human  TMCs  through  the  exposure  to  growth  factors
involved  in  development  of  the  anterior  segment;
2.  To  investigate  the  morphological  and  transcriptome  profiles  created  by  Cell  Painting  and
scRNA-seq  in  TMCs,  where  genes  implicated  in  IOP  variation  have  been  knocked  out  by
CRISPR.
Methods:  
DP-MSCs  were  treated  with  retinoic  acid  (RA),  TGF-β  super-family  members  transforming  
growth  factor-β2  (TGF-β2)  and  bone  morphogenetic  protein  4  (BMP4)  for  5  days.  The  
expressions  of  TMCs  markers  were  investigated  by  qRT-PCR,  functional  TM  cell  
characteristics  were  profiled  by  a  collagen  contraction  assay,  dexamethasone-induced  
myocilin  secretion  and  through  phagocytosis  assessment.   
To  investigate  genes  associated  with  IOP,  a  clustered  regularly  interspaced  short  palindromic 
repeats  (CRISPR)  knockout  screen  was  performed  by  transfecting  the  TMCs  with  lentivirus  
carrying  the  single-guide  RNAs  (sgRNAs)  targeting  62  genes  across  53  loci,  together  with  5  
human  non-targeting  controls,  in  arrayed  format.  Cells  were  then  seeded  to  the  image  plates  
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by  flow  cytometry  for  high-throughput  morphological  profiling  assay,  or  pooled  for 
single-cell  RNA  sequencing  (scRNA-seq).  
Results:  
After  5  days  of  treatment  with  the  combination  of  the  three  transcription  factors,  RA,  TGF-β2 
and  BMP4  in  the  DP-MSCs,  the  TMCs  marker  MYOC  were  significantly  upregulated,  and  
the  secreted  myocilin  was  also  upregulated  determined  by  ELISA;  however,  the  expression  of 
MYOC  was  not  increased  or  induced  following  dexamethasone  exposure  and  the  contractility  
of  collagen  gel  was  also  not  observed.  
A  total  of  210,  234  cells  were  individually  segmented  and  image-based  profiling  performed  
for  CRISPR/Cas  edited  TM  cells.  A  total  of  910  morphological  features  were  extracted  for  
each  of  the  gene  knockout  perturbations.  Cells  clustered  into  2  major  groups  via  unstructured  
hierarchical  clustering.  Significant  features  of  the  clusters  were  extracted  related  to  the  
granularity  of  the  golgi  apparatus  and  mitochondrial.  For  transcriptional  profiling  a  total  of  
25,879  single  cells  were  demultiplexed  and  had  their  corresponding  sgRNA  identified.  A  
total  of  240  differentially  expressed  genes  (DEGs)  were  identified  and  expression  profiles  
with  these  genes.  The  profiles  were  also  clustered  into  2  groups  via  hierarchical  clustering,  
the  DEGs  related  to  the  difference  of  the  2  clusters  are  involved  in  the  interferon  alpha/beta  
signaling.   
Conclusion:  
Although  DP-MSCs  express  markers  of  trabecular  meshwork  cells  following  the  exposure  of  
a  combination  of  transcription  factors,  they  were  found  not  to  acquire  morphological  profiles  
characteristic  of  trabecular  meshwork  function.  High  throughput  analysis  of  cellular  structure 
and  function  through  cellpainting  and  scRNA-seq  assays  enabled  the  direct  study  of  genetic  
perturbations  at  the  single  cell  resolution.  This  work  provides  a  framework  for  investigating  
the  role  of  genes  involved  in  the  pathogenesis  of  glaucoma  in  both  genetic  and  morphology.  
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1.  INTRODUCTION
1.1  Prevalence  of  glaucoma  
Glaucoma  is  a  heterogeneous  group  of  diseases  defined  by  characteristic  optic  damage  and  
vision  loss.  The  glaucomas  are  categorized  by  the  iridocorneal  angle  into  open-angle  
glaucoma,  angle-closure  glaucoma,  or  developmental  (congenital)  glaucoma,  with  a  further  
classification  of  primary  and  secondary  types  1,2 .  As  the  leading  cause  of  irreversible  
blindness  in  the  world,  more  than  60  million  people  were  affected  by  this  disease  in  2010,  
and  this  number  was  estimated  to  increase  to  80  million  by  2020,  and  of  these,  approximately 
three  out  of  four  people  would  have  open-angle  glaucoma  2 .  The  potential  glaucoma  patients  
in  Australia  were  382  950  in  2012,  which  accounts  for  nearly  3.7%  of  people  over  40  years  
old  3 .  As  the  population  ages,  the  prevalence  of  glaucoma  is  expected  to  rise  even  higher  3 .  
Furthermore,  the  cost  of  glaucoma  is  a  significant  economic  burden  to  the  Australian  
healthcare  system,  which  is  estimated  to  increase  to  $AU784  million  by  2025  4 .   
1.2  The  pathology  of  primary  open-angle  glaucoma  
Primary  open-angle  glaucoma  (POAG)  is  the  most  common  glaucoma  subtype.  Several  risk  
factors  are  attributed  to  the  progression  of  POAG.  These  include  older  age,  family  glaucoma  
history,  some  ethinic  groups,  use  of  corticosteroids,  and  high  intraocular  pressure  (IOP)  5 .  
Normal  IOP  ranges  from  12mmHg  to  22  mmHg  and  it  is  the  only  known  modifiable  risk  
factor  of  POAG.  Previous  studies  show  that  elevated  IOP  above  22mHg  is  strongly  related  to 
optic  nerve  damage,  thought  to  be  triggered  by  a  series  of  cellular  events  leading  to  the  death  
of  retinal  ganglion  cells  (RGCs).  Under  the  presence  of  the  elevated  IOP,  the  retrograde  
delivery  of  trophic  factors  such  as  brain-derived  neurotrophic  factor  is  interrupted  and  
reactive  oxygen  species  (ROS)  accumulate  in  the  retina  which  results  in  glial  cell  activation.  
This  especially  occurs  in  the  lamina  cribrosa  where  the  sclera  is  perforated  by  the  passing  of  
the  optic  nerve  fibers  6–9 .  Studies  in  mouse  models  show  that  activated  glial  cells  (astrocytes)  
secrete  tumor  necrosis  factor  α  (TNF-α),  which  leads  to  the  loss  of  RGC  axons  and  then  the  
death  of  the  whole  cell  10 .  Due  to  the  structural  changes  of  the  optic  nerve  head,  the  cup  
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becomes  larger  and  deeper  with  the  loss  of  the  prelaminar  tissue.  This  can  be  observed  
through  fundus  examination  and  plays  a  critical  role  in  the  diagnosis  of  glaucoma  ( Fig.  1 ).  
Glaucomatous  optic  damage  is  also  observed  in  the  normal-tension  glaucoma  (NTG)  patients 
whose  IOP  is  in  the  12mmHg  to  22mmHg  range.  In  NTG  patients,  the  low  cerebrospinal  
fluid  pressure  or  intracranial  pressure  resulting  in  a  relatively  higher  IOP  is  supposed  to  play  
a  role  in  the  development  of  glaucoma  11–13   .   
Figure  1:  Elevated  intraocular  pressure  leads  to  progressive  damage  of  the  optic  nerve.  A) 
Normal  intraocular  pressure;  B)  High  intraocular  pressure.  Figure  created  with  
Biorender.com  
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1.3  Genetics  of  primary  open-angle  glaucoma  
POAG  is  considered  to  be  a  disease  resulting  from  the  interaction  between  multiple  genes  and 
environmental  factors.  Through  genetic  linkage  analysis,  three  genes  associated  with  POAG  
have  been  identified,  myocilin  ( MYOC ),  optineurin  ( OPTN ),  and  TANK-binding  kinase  
( TBK1 )  14–16 .   
Many  studies  have  shown  the  MYOC  variants  cause  dysfunction  of  trabecular  meshwork  cells 
(TMCs),  leading  to  an  elevated  IOP  (discussed  in  detail  in  later  paragraphs)  1,17,18 .  OPTN  and  
TBK1  share  a  common  pathway  in  NTG,  and  both  of  these  gene  variants  are  also  related  to  
amyotrophic  lateral  sclerosis,  a  disease  of  the  central  nervous  system  18,19 .  Recently,  an  
advanced  technique  of  genome-wide  association  studies  (GWAS)  was  applied  to  investigate  
the  genetic  associations  for  POAG.  GWAS,  based  on  the  next  generation,  high-throughput  
DNA  sequencing,  can  identify  positive  single  nucleotide  polymorphisms  (SNPs)  via  
analyzing  hundreds  of  thousands  of  SNPs  from  individuals  in  case  and  control  groups  20 .  
Many  POAG  associated  loci  have  been  found,  which  include  Caveolin  1  and  2  ( CAV1/CAV2 ), 
transmembrane  and  coiled-coiled-coil  domains  1  ( TMCO1 ),  cyclin-dependent  kinase  
inhibitor  2B  antisense  RNA  1  ( CDKN2B-AS1 ),  SIX  homeobox  6  ( SIX6 ),  ATB  binding  
cassette  subfamily  A  member  1  ( ABCA1 ),  actin  filament  associated  protein  1  ( AFAP1 ),  
GDP-mannose  4,6-dehydratase  ( GMDS ),  Forkhead  Box  C1  ( FOXC1 ),  thioredoxin  reductase  
2  ( TXNRD2 ),  Ataxin  2  ( ATXN2 )  21–24 .  Although  the  mechanistic  role  of  these  gene  variants  in  
POAG  remains  to  be  investigated,  their  potential  affected  site  can  be  predicted  by  current  




Table  1:  POAG-associated  genomic  regions  identified  by  GWAS  
  
  
A  recent  GWAS  meta-analysis  identified  85  novel  SNPs  associated  with  IOP  using  data  from  
the  UK  Biobank,  the  International  Glaucoma  Genetic  Consortium  and  the  Australian  &  New  
Zealand  Registry  of  Advanced  Glaucoma  Cohort  33 .  Novel  gene  variants  associated  with  
POAG  and  IOP  were  discovered,  including  ANGPT1,  ANKH,  MECOM  and  ETS1,  which  
may  play  an  important  role  in  the  maintenance  of  IOP.  Interestingly,  this  study  also  identified  
SNPs  associated  with  corneal  parameters,  such  as  ADAMTS6  (central  corneal  thickness),  
MYOF,  ANAPC1,  GLIS3 ,  and  FNDC3B  (corneal  hysteresis)  33 .  Thus,  GWAS  has  provided  us  
the  gene  candidates  related  to  POAG,  but  their  roles  in  the  pathogenesis  of  POAG  remains  to  
be  investigated.   
  
1.4  Anatomy  of  the  trabecular  meshwork  
1.4.1  Circulatory  system  in  the  anterior  segment  of  the  eye  
IOP  is  maintained  by  the  circulatory  system  in  the  anterior  segment  of  the  eye.  Aqueous  
humor  is  produced  by  the  ciliary  body,  and  then  passes  through  the  pupil  from  posterior  
chamber  to  anterior  chamber  to  nourish  the  non  vascularized  tissue  structures,  i.e.,  the  lens,  
cornea,  and  the  trabecular  meshwork  (TM).  Finally,  Aqueous  humor  drains  through  the  TM  
to  Schlemm's  canal  in  the  iridocorneal  angle,  then  flows  back  to  the  episcleral  blood  vessels  
4  
Nearest  Gene  Potential  affected  site  
CAV1/CAV2  IOP  25   
CDKN2B-AS1 RGC  26   
SIX6   RNFL  and  IOP  27,28   
TMCO1   IOP  22   
AFAP1  retina,  optic  nerve,  and  TMCs  23   
ABCA1  Retina  and  TMCs  18,23,29   
TXNRD2  RGC  24,30   
FOXC1/GMDS  Eye  development  23,31   
ATXN2  RGC 32   
  
( Fig.  2 ).  Elevated  IOP  generally  results  from  reduced  aqueous  outflow  in  both  open-angle  
glaucoma  and  angle-closure  glaucoma,  while  TM  plays  a  significant  role  in  the  elevated  IOP  
in  open-angle  glaucoma  1,34 .   
  
Figure  2:  The  generation  and  flow  of  aqueous  humor  flow  in  the  anterior  segment  of  the  eye.  




1.4.2  Anatomy  of  the  trabecular  meshwork  
The  human  TM  is  a  three-sided  prismatic  tissue  located  in  the  angle  of  the  anterior  chamber  
of  the  eye  ( Fig.  2 ).  The  unique  location  indicates  that  the  TM  plays  a  major  role  in  the  
maintenance  of  aqueous  humor.  Approximately  80%  of  total  aqueous  humor  outflow  is  
carried  by  the  TM  and  the  remaining  aqueous  humor  outflow  is  carried  by  uveoscleral  
outflow  5,35,36 .  The  spongy  TM  tissue  allows  aqueous  humor  to  flow  from  the  anterior  
chamber  into  Schlemm’s  canal.  Histologically,  the  TM  is  divided  into  three  parts:  the  inner  
uveal  trabecular  meshwork,  which  is  from  the  anterior  chamber  to  Schemm’s  canal,  the  
corneoscleral  trabecular  meshwork,  and  the  endothelial  meshwork,  also  known  as  
juxtacanalicular  tissue  (JCT)  37 .  The  uveal  meshwork  consists  of  one  to  two  layers  of  TMCs  
which  form  long,  narrow  beams,  covered  by  elliptical  nuclei  endothelial  cells,  with  large,  
irregular  spaces  between  beams.  The  corneoscleral  meshwork  consists  of  8  to  14  layers  and  
beams  are  broad  and  flat  with  the  spaces  between  them  becoming  smaller  37 .  The  JCT  
meshwork,  which  is  adherent  to  the  endothelium  of  Schlemm’s  canal,  does  not  form  lamellae  
5  
or  connective  tissue  beams,  instead,  it  consists  of  2  to  5  layers  of  scattered  cells  in  connective  
tissue,  with  the  cells  embedded  in  a  loosely  arranged  tissue  extracellular  matrix  38 .  Thus,  the  
intertrabecular  spaces  in  each  of  the  three  parts  become  smaller,  which  means  the  resistance  
of  the  aqueous  humor  is  increased  from  the  inner  uveal  meshwork  to  JCT.  As  such,  when  IOP 
is  increased,  the  outermost  part  of  TM  takes  most  of  the  outflow  resistance  39 ( Fig.  3 ).   
Figure  3:   Light  micrograph  of  a  meridional  section  through  the  trabecular  meshwork  38 .  
TM:  Trabecular  meshwork;  SS:  Scleral  spur ;  CM:  Ciliary  muscle ;  AC:  Anterior  chamber ;  
JCT:  Juxtacanalicular  tissue,  2-5  layers  of  scattered  cells;  CTM:  Corneoscleral  trabecular 
meshwork,  8-14  layers  of  broad  and  flat  beams;  UTM:  Uveal  trabecular  meshwork,  1-2 
layers  of  beams  with  large  and  irregular  spaces.  Scale  bars:  20  μm  (A),  5  μm  (B).  
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1.4.3  The  role  of  trabecular  meshwork  in  primary  open-angle  glaucoma  
In  POAG  patients,  structural  alterations  can  be  observed  in  the  TM  which  are  considered  to  
increase  the  outflow  resistance  1,40–42 .  Decreased  cellularity  of  the  TM  is  common  in  
POAG.This  can  result  from  the  migration,  phagocytosis,  and  the  apoptosis  of  the  TMCs,  with  
cell  apoptosis  potentially  caused  by  oxidative  stress,  mechanical  stress,  or  trabecular  
hypoperfusion  43 .  Another  structural  change  common  to  PAOG-affected  trabecular  tissue  is  
increased  extracellular  matrix  (ECM)  components.  This  may  result  from  the  increased  
concentration  of  transforming  growth  factor  β  (TGF-β2)  in  aqueous  humor  44 .  Studies  have  
shown  when  mouse  and  human  TM  cells  were  treated  with  TGF-β2,  the  production  of  
connective  tissue  growth  factor  would  increase,  which  results  in  actin  polymerization  and  
ECM  production.  Also,  TGF-β2  could  upregulate  the  production  and  secretion  of  fibronectin,  
which  contributes  to  the  increased  ECM  deposition  to  reduce  the  outflow  facility  45,46 .  Thus,  
the  status  of  TMCs  plays  an  important  role  in  the  structural  alteration  in  TM  tissue,  and 
TGF-β2  signaling  is  a  contributor  to  pathogenesis.   
  
1.4.4  The  role  of  MYOC  mutations  in  trabecular  meshwork  
MYOC  was  the  first  reported  gene  associated  with  glaucoma  through  genetic  linkage  analysis.  
MYOC  mutations  account  for  about  4%  of  adult  POAG  cases  and  more  than  10%  of  
juvenile-onset  cases  1,14 ,  and  approximately  90%  of  the  carriers  of  MYOC  mutations  would  
develop  glaucoma  phenotypes.  To  date,  282  variants  have  been  documented  in  the  MYOC  
gene,  85.1%  of  which  are  missense  mutations  and  40%  result  in  POAG  47   
( http://www.myocilin.com/ ,  accessed  March   2020).  Moreover,  myocilin  allele-specific  
glaucoma  patients  typically  have  high  levels  of  IOP  48,49 .  The  mechanisms  of  myocilin  
allele-specific  glaucoma  remain  unclear.  Overexpression  or  downregulation  of  myocilin  does  
not  generate  glaucoma  in  mice  models  50,51 .  However,  glaucoma-related  MYOC  mutations  
could  change  the  structure  of  myocilin,  altering  the  properties  of  the  protein.  An  early  study  
found  the  solubility  of  mutant  myocilin  was  reduced  in  Triton-X  100  52 .  Study  of  the  crystal  
structure  has  shown  myocilin  contains  an  olfactomedin  domain,  which  is  a  five-bladed  
β-propeller  structure  involved  in  protein-protein  interaction.  Several  glaucoma-associated  
MYOC  mutations  are  located  within  or  near  this  binding  site  53,54 .  The  alteration  of  the  protein  
binding  properties  may  result  in  the  aggregation  of  mutant  myocilin,  which  is  toxic  to  TMCs  
( Fig.  4 )  55 .  Myocilin  aggregates  could  initiate  a  series  of  events  such  as  endoplasmic  
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reticulum  (ER)  stress,  the  increase  of  ROS,  and  the  impairment  of  mitochondrial  function,  
which  would  finally  result  in  the  dysfunction  of  TMCs  5,55,56 .   
Previous  research  demonstrates  how  the  structure  of  the  TM  facilitates  the  outflow  of  fluid  
from  the  eye  and  maintains  a  healthy  IOP.  When  this  structure  is  perturbed  due  to  cell  death  
or  dysfunction  from  MYOC  mutations,  oxidative  or  mechanical  stress,  hypoperfusion,  excess  
ECM  or  unknown  causes,  the  TM  function  is  compromised  and  glaucoma  can  develop.  
  
Figure  4:  Schematic  representation  of  the  retention  of  mutant  myocilin  in  trabecular  
meshwork  cells,  figure  created  with  Biorender.com .  
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1.5  Treatments  for  open  angle  glaucoma  
1.5.1  Currently  available  treatments   
The  only  proven  treatment  for  glaucoma  is  to  decrease  the  IOP  57 .  Currently,  medication  for  
lowering  IOP  mainly  focuses  on  reducing  the  production  of  aqueous  humor ,  such  as  
β-adrenergic  blockers,  or  increasing  the  uveoscleral  outflow,   such  as  prostaglandin  58 .  IOP  
should  be  lowered  toward  a  target  level,  which  is  usually  20%  to  50%  reduction  in  the  initial  
pressure  5 .  When  medical  treatment  cannot  achieve  the  target,  laser  trabeculoplasty  or  
trabeculectomy  may  be  necessary.   
  
1.5.2  Emerging  new  drugs  for  glaucoma  
Although  not  many  medications  targeting  the  TM  for  glaucoma  have  been  approved  yet,  
considering  the  TM  tissue  carries  about  80%  outflow  of  the  aqueous  humor ,  this  is  a  
promising  area  for  research.  Rho  kinase  (ROCK)  inhibitors  can  lower  IOP  by  acting  on  the  
TM  59 .  The  Rho  family  is  a  group  of  G-proteins  including  Rho,  Rac,  and  CDC42.  When  
bound  to  guanosine  triphosphate,  the  protein  effector  molecules,  Rho  kinases,  stimulate  the  
polymerization  of  actin  stress  fibers  and  focal  adhesions  formation.  These  events  enhance  the  
tissue  contraction  by  binding  cells  to  the  ECM.  Thus,  ROCK  inhibitors  can  weaken  the  cell  
binding  to  its  ECM,  leading  to  wider  spaces  in  the  TM  and  reduced  flow  resistance.  
Furthermore,  ROCK  inhibitors  can  slow  the  progression  of  corticosteroid-induced  glaucoma  
by  suppressing  ECM  production  36,41 .  To  date,  only  two  ROCK  inhibitors  are  approved  for  
clinical  use,  compound  28  (fasudil)  and  compound  165  (ripasudil).  As  the  first  ROCK  
inhibitor  for  glaucoma  treatment,  ripasudil  shows  a  significant  effect  on  IOP,  which  could  
lead  to  a  decrease  of  3.4  mmHg  compared  to  baseline  (0.4%  eye  drops,  twice  daily)  59 .  
However,  conjunctival  hyperemia  is  commonly  observed  in  clinical  trials,  and  ripasudil  could  
reduce  the  bioavailability  of  timolol  (β-adrenergic  blockers)  59,60 .  These  side  effects  prevent  
ripasudil  from  being  the  first  choice  for  glaucoma  management,  but  there  are  still  other  
ROCK  inhibitors  in  clinical  trials  such  as  AR-13324  and  AMA0076. 59   
  
Other  candidates  target  the  oxidative  stress,  since  TM  is  the  most  sensitive  tissue  to  oxidative  
damage  in  the  anterior  ocular  segment  61 .   A  number  of  antioxidants  could  be  potentially  
applied  to  suppress  the  production  of  ROS.  Luna,  et  al.  (2009)  found  that  when  primary  
porcine  TM  cells  were  treated  with  resveratrol  (25μM)  for  15  days,  the  production  of  ROS  
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and  associated  inflammatory  markers  including  IL  1α,  IL6,  and  IL8  are  effectively  prevented  
and  that  cell  proliferation  was  not  influenced  by  resveratrol  62 .  Fatty  acid  omega-3  also  has  
preventive  effects  against  oxidative  stress  induced  by  H 2 O 2   in  primary  human  TMCs,  and  has  
been  suggested  for  glaucoma  prevention 63 .  Other  substances  such  as  vitamins  C  and  E,  
creatine,  α-lipoic  acid,  nicotinamide,  and  catechins  also  have  antioxidant  effects,  but  their  
effect  on  TM  is  unknown.  64    
  
Another  approach  is  using  sodium  4-phenylbutyrate  (PBA)  for  myocilin  related  glaucoma.  
This  small  chemical  chaperone  is  able  to  correct  protein  folding  abnormalities  and  restore  the  
function  of  mutant  cystic  fibrosis  transmembrane  conductance  regulator  protein  on  the  cell  
surface  65 .  Zode  et  al.  (2011,  2012)  reported  that  PBA  could  help  the  secretion  of  mutant  
myocilin  in  TMCs  of  mice  and  reduce  the  ER  stress  induced  by  tunicamycin  66,67 .   
Ultimately  full  understanding  of  the  pathogenesis  of  the  disease  can  contribute  to  finding  new  
drugs  for  glaucoma  treatment,  in  addition  to  those  that  decrease  the  IOP.   
  
1.6  Models  of  glaucoma  
To  investigate  the  biology  of  POAG,  both  in  vivo  models  and  in  vitro  models  have  been  
applied.  In  vivo  models  have  more  relevance  to  clinical  glaucoma,  but  come  with  a  higher  
cost  for  animal  breeding  and  maintenance.  In  vitro  models,  including  cells  and  organ  culture,  
are  more  controllable  for  precise  conditions,  but  have  less  relevance  to  glaucoma  compared  to  
in  vivo  models  68 .  Overcoming  these  limitations  and  gaining  a  deeper  understanding  of  
existing  models  will  increase  research  power  for  developing  POAG  therapies.  
  
1.6.1  In  vivo  models  
To  study  the  response  of  the  ocular  tissues  to  glaucoma,  animals  such  as  macaque  monkeys  
and  transgenic  mice  have  been  applied.  Yucel  et  al  (1999)  observed  that  decreased  myelinated  
nerve  fiber  was  associated  with  elevated  IOP  in  monkey  models  69 .  Ju  et  al  (2008)  found  that  
increased  IOP  damaged  mitochondria  in  the  optic  nerve  in  transgenic  mice  70 .  More  recently,  
Zhu  et  al.  (2016)  restored  the  normal  function  of  TM  via  transplanting  the  TM-like  cells  into  




1.6.2  In  vitro  models  
Cell  models  are  also  widely  applied  to  studies  of  glaucoma  pathogenesis,  drug  screening  and  
potential  therapeutic  treatments.  These  cells  can  be  derived  from  human  or  animal  ocular  
tissue  such  as  TM,  Schlemm’s  canal  endothelium,  and  retinal  neurons  72,73 .  TMCs  can  be  
harvested  by  treating  TM  tissue  with  collagenase-A  and  culturing  in  artificial  medium  74 .  
These  cells  can  be  induced  to  mimic  the  progression  of  glaucoma  by  various  methods,  e.g.  
being  exposed  to  chemical  compounds  including  dexamethasone,  transforming  growth  
factor-β2,  and  oxidative  stress  factors  such  as  H 2 O 2   56,75,76 .  Also,  primary  human  TMCs  can  be  
transfected  with  reconstructed  plasmids  containing  mutant  myocilin  gene  to  induce  
mitochondrial  function  deficits  and  ROS  generation 56 .  However,  primary  TMCs  start  to  
develop  senescence  features  such  as  increased  size,  vacuoles,  and  reduced  doubling  time  by  
passage  9  or  10  in  vitro,  and  the  gene  expression  patterns  also  differ  from  early  passage  
TMCs.  Hence,  it  is  preferable  to  use  TMCs  from  human  eyes  before  passage  7  77 .  This  has  led  
to  demand  to  generate  TMCs  from  stem  cells,  as  it  is  sometimes  not  feasible  to  harvest  
enough  TMCs  from  living  eyes  in  glaucoma  patients.   
  
1.7  Cultured  trabecular  meshwork  cell  models  generation  
1.7.1  The  development  of  trabecular  meshwork   
To  generate  a  feasible  differentiation  procedure,  we  reviewed  the  development  pathway  of  
TM  tissue.  In  the  development  of  the  anterior  ocular  segment,  the  TM  and  Sclemm’s  canal  
become  differentiated  from  15 th   to  20 th   week  of  gestation,  shortly  after  the  start  of  iris  
elongation.  Briefly,  a  dense  collection  of  mesenchymal  cells  aggregate  in  the  chamber  angle  
and  begin  to  elongate  and  flatten,  becoming  separated  from  each  other  by  spaces  which  are  
then  filled  with  extracellular  fibers.  The  fibers  then  become  organized  into  lamellae  or  beams  
and  covered  by  flat,  endothelial-like  cells.  The  formation  of  TM  tissue  should  be  completed  
around  birth  in  humans 78 .  Cell  grafting  and  cell  labelling  experiments  in  mice  have  
demonstrated  that  the  ocular  mesenchymal  cells  are  derived  from  both  cranial  neural  crest  
and  cranial  paraxial  mesoderm 79 .   A  series  of  growth  factors  and  transcription  factors  act  on  
the  mesenchymal  stem  cells  (MSCs)  to  differentiate  them  to  TMCs.  
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1.7.2  Transcription  factors  involved  in  the  differentiation  of  trabecular  meshwork   
Retinoic  acid  (RA)  is  indispensable  for  the  development  of  the  eyes.  The  RA  signal  is  
transduced  by  two  families  of  nuclear  receptors,  retinoic  acid  receptor  (RAR)  family  (RARα,  
RARβ,  and  RARγ)  and  retinoid  X  receptor  (RXR)  family  (RXRα,  RXRβ,  and  RXRγ).  These  
receptors  work  in  the  form  of  RXR/RAR  heterodimers  80 .  In  periocular  mesenchyme  (POM),  
RA  signaling  is  generated  via  the  activation  of  RXRα/RARβ,  and  RXRα/RARγ.  This  
signaling  pathway  plays  an  important  role  in  embryonic  development,  cell  proliferation,  
differentiation  and  apoptosis,  thus  blocking  RA  signaling  could  cause  early  embryonic  death  
81,82 .  Also,  impairment  of  RA  synthesis  could  affect  the  expression  of  FOXC1  and  paired-like  
homeodomain  2( PITX2 ),  which  are  both  required  for  eye  development  81 .  The  FOXC1  
transcription  factor  is  expressed  when  mesenchymal  cells  have  migrated  into  the  eye.  In  
FOXC1 -/-   mice  models,  severe  anterior  segment  developmental  defects  are  observed,  
including  thickened  cornea  epithelium,  disorganized  stroma,  and  the  absence  of  anterior  
chamber  due  to  the  lens  not  being  separated  from  the  cornea.  In  FOXC1 +/-   mice  models,  
though  the  abnormalities  are  milder,  all  mice  show  hypoplastic  TM  and  Schlemm’s  canal  
histologically  31,83 .  PITX2  is  also  a  transcription  factor  expressed  in  the  POM  and  its  
expression  pattern  is  very  similar  to  FOXC1 .  Both  deficiency  and  over-expression  of  PITX2  
causes  human  ocular  anterior  segment  dysgenesis,  which  indicates  that  normal  anterior  
segment  development  needs  precise  regulation  of  transcription  factors  via  various  signaling  
pathways  31 .  The  transforming  growth  factor  β  (TGFβ)  superfamily  signaling  pathway  also  
plays  an  important  role  in  ocular  development.  This  super-family  contains  a  group  of  
signaling  molecules  which  affect  a  series  of  biological  processes,  such  as  cell  proliferation,  
differentiation,  migration,  and  apoptosis  84 .  BMP4  (bone  morphogenetic  protein  4)  belongs  to  
this  superfamily  and  is  expressed  during  ocular  development.  BMP4  +/-   mice  showed  various  
degrees  of  anterior  segment  dysgenesis,  including  the  TM,  which  exhibits  a  decrease  in  the  
trabecular  beams  and  ECM  85 .  BMP4  also  influences  the  cell  migration  and  differentiation  via  
regulating  the  expression  of  ECM 31 .  Another  transcription  factor,  TGF-β2  also  plays  an  
essential  role  in  ocular  development.  TGF-β2  is  mainly  expressed  by  the  lens,  and  it  is  
required  for  the  expression  of  FOXC1  and  PITX2  in  the  formation  of  TM  and  neural  
crest-derived  cornea  86 .   
  
Overall,  when  RA  signaling  and  TGFβ  signaling  occurs,  MSCs  may  potentially  exhibit  some  
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characteristic  properties  of  TMCs  or  POM.  We  hypothesized  that  when  treated  with  RA,  
BMP4  and  TGF-β2,  mesenchymal  stem  cells  could  express  the  gene  markers  and  exhibit  the 
functional  properties  of  TMCs.   
  
1.7.3  Identification  of  trabecular  meshwork  cells  
In  order  to  verify  that  MSCs  have  successfully  undergone  differentiation  into  TMCs  they  
ideally  need  to  display  the  morphologic  features,  specific  protein  markers,  and  the  cell  
behaviors  of  TMCs.  TMCs  are  morphologically  similar  to  fibroblast,  which  have  an  elliptical,  
speckled  nucleus  surrounded  by  branched  cytoplasm  ( Fig.  5 ).  There  is  not  a  single  specific  
protein  marker  for  TMCs  yet.  However,  studies  have  identified  TM-like  cells  differentiated  
from  iPSCs  through  the  expression  of  a  group  of  proteins  including  Col  IV,  laminin,  matrix  
Gla  ( MGP ),  and  α-SMA,  among  others.  87–89 .  Stamer  et  al.  (2017)  reviewed  the  characteristics  
of  TMCs,  which  provides  more  information  on  specific  TMC  features  ( Table  2 ). 90    
  
Figure  5:  The  appearance  of  fibroblast  and  trabecular  meshwork  cells,  80%  confluent.  A)  
Fibroblast;  B)  human  primary  HTMCs.  Scale  bar:  20  μm  
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Table  2:  Identification  of  TM  cells  in  culture  90   
  
  
One  of  the  behavioural  properties  of  TMCs  is  upregulated  expression  of  MYOC  protein  upon  
corticosteroid  treatment,  and  that  this  behaviour  is  not  shared  by  neighboring  cells  90,91   .  A  
possible  mechanism  is  that  corticosteroids  such  as  dexamethasone  regulate  the  activity  of  
calcineurin/NFATc1  which  promotes  the  expression  of  myocilin  91,92 .  The  TMCs  are  also  
phagocytic,  as  demonstrated  by  Ding,  et  al’s  2014  study  using  pHrodo  fluorescent  
bioparticles  87 .  Another  essential  feature  is  the  ability  to  contract  to  the  extracellular  matrix  
(ECM).  TMCs  can  contract  their  extracellular  collagen  due  to  the  adhesiveness  of  the  cell  to  
its  matrix  and  the  activation  of  the  actin  cytoskeleton.  As  mentioned,  this  can  be  prevented  by  
ROCK-inhibitors, 93,94   which  is  an  alternate  means  to  screen  for  TMC-like  behaviour.   
  
TMCs  can  be  identified  by  the  combination  of  protein  markers  and  behavioural  
characteristics  as  well  as  their  morphology.  In  order  to  analyse  these  features,  high  
throughput,  human-independent  methods  are  preferred  for  accurate  and  detailed  
characterisation  of  cells.   
14  
Positive  Markers  Negative  Markers  Cellular  responses  
Myocilin  VE-cadherin  Acetylated  LDL  uptake  
Matrix  GLA  
protein  
Fibulin-2  αvb5/β3-mediated  phagocytosis  
Chitinase-3  like-1  Integrin  α6  CS  induction  of  myocilin,  FN,  CLANs  
Aquaporin-1 Keratin  CS  down  regulation  of  tPA,  phagocytosis  
Smooth  muscle  
actin  
Desmin  PMA,  TNFα  and  IL-1α  stimulation  of  
MMP-3/-9  
Smooth  muscle  
myosin  
VEGFR3  TGFβ  induction  of  alpha-B  crystallin,  PAI-I,  
MMP2,  CLANs  
Alpha-B  crystallin  Prox-1  Stretch  induction  of  MMP-2/-3  
  
  
1.8  High  throughput  analysis  of  gene  function  
New  technology  including  c lustered  regularly  interspaced  short  palindromic  repeats  
(CRISPR)  technology,  automated  microscopy  and  single  cell  RNA  sequencing  (scRNA-seq)  
have  improved  large-scale  gene  function  analysis  by  morphological  profiling  and  mRNA  
expression  profiling.  These  methods  allow  researchers  to  quickly  and  accurately  characterise  
large  numbers  of  cells,  as  well  investigate  the  effect  of  many  different  single  genes  knockouts  
in  a  single  experiment.   
  
1.8.1  CRISPR  technology  in  high-throughput  genetic  screens  
CRISPR  is  an  RNA-mediated  defense  system  found  in  bacteria  and  archaea,  designed  to  
defend  against  viruses  and  plasmids,  that  has  been  adapted  for  genome  editing  within  living  
cells  95–100 .  This  system  contains  a  cas  endonuclease  protein  and  a  single-guide  RNA  
(sgRNA),  which  form  the  Cas-sgRNA  ribonucleoprotein  complex.  This  complex  localises  to  
a  target  DNA  sequence  following  guide  RNA:genomic  DNA  base-pairing  rules  97 .  The  most  
commonly  used  CRISPR  system  utilises  Streptococcus  pyogenes  Cas9  (SpCas9).  When  the  
SpCas9-sgRNA  complex  recognises  the  target  DNA  sequence,  a  double-strand  break  is  
created.  In  eukaryotic  cells,  DSBs  can  be  repaired  through  non-homologous  end  joining  
(NHEJ)  and  homology-directed  repair  (HDR).  NHEJ  generally  occurs  more  efficiently  than  
HDR  and  results  in  stochastic  insertions  and  deletions  (indels)  101,102 .  If  NHEJ  occurs  in  a  
coding  region,  it  can  introduce  a  frameshift  mutation  which  causes  loss-of-function  in  the  
targeted  gene  99 .  With  the  ease  of  desired  DNA  sequence  targeting,  the  CRISPR  system 
enables  us  to  develop  cell  and  animal  knockouts  which  can  be  used  to  explore  the  causal  
linkages  between  genetic  variations  and  biological  phenotypes.  Researchers  have  applied  this  
powerful  tool  to  high-throughput  analysis  to  determine  gene  function,  identify  drug  targets  
and  explore  cellular  signaling  pathways 103 .  Cas9-mediated  knockout  screening  has  been  a  
very  successful  method  in  many  previous  studies.  In  these  experiments,  libraries  were  
designed  with  at  least  two  sgRNAs  targeting  each  gene  to  increase  the  likelihood  of  a  
knockout,  and  the  CRISPR  system  was  delivered  into  mammalian  cells  via  viruses.  Chen  et  
al.  (2015)  identified  a  set  of  genes  driving  tumor  growth  and  metastasis  in  mice  models  104 .  
Shi  et  al.  (2015)  identified  25  drug  targets  in  murine  acute  myeloid  leukemia,  in  which  6  were  
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known  drug  targets  105 .  Parnas  et  al.  (2015)  reported  dozens  of  novel  regulators  of  Tlr4  
signaling  in  the  host  response  to  pathogens  106 .  Zhou  et  al.  (2014)  identified  host  genes  
essential  for  the  bacterial  toxins  against  anthrax  and  diphtheria  toxins  107 .  Also,  the  
Cas9-mediated  knockout  screens  show  a  much  higher  reagent  consistency  for  the  hits  in  the  
Cas9  screen  compared  to  the  previous  gene  knockdown  technique  of  RNAi  (RNA  
interference)-based  screens  103 .  Thus,  CRISPR  can  be  used  to  generate  a  robust  model  with  
desired  gene  perturbation  in  large-scale  experiments.  CRISPR  has  also  been  applied  to  other  
ocular  experiments.  Hung  et  al.  (2016)  delivered  the  CRISPR/Cas9  system  to  the  retinal  of  
transgenic  mice  via  adenovirus,  successfully  disrupted  the  expression  of  yellow  fluorescent  
protein  to  assess  the  gene  editing  efficacy  108 .  Jain  et  al.  (2017)  knocked  down  mutant  MYOC  
via  adenovirus  mediated  CRISPR/Cas9  system  in  human  TMCs  and  a  murine  model,  and  the  
ER  stress  was  released  109 .  However,  there  has  been  no  large-scale  CRISPR  mediated  
experiment  undertaken  for  any  ophthalmic  application  ocular  research  yet.  
  
1.8.2  Image-based  profiling  
Automated  microscopy  enables  us  to  perform  large-scale  imaging  experiments  and  create  an  
image  based-profile  of  each  cell  population.  These  profiles  contain  complex  phenotypic  
outcomes  that  are  related  to  the  disease  states  or  responses  in  a  drug  screening.  Bray  et  al.  
(2016)  summarized  the  method  named  “Cell  Painting”  to  evaluate  the  biological  information  
about  cellular  state  110 .  In  Cell  Painting,  cultured  cells  are  dyed  by  six  fluorescent  stains  to  
reveal  eight  cellular  substructures.  After  imaging  in  five  channels,  we  are  able  to  extract  more  
than  1000  morphological  features  from  each  of  the  cells  by  designing  pipelines  with  
cellprofiler  software.  This  method  has  been  applied  to  compound  library  enrichment  and  
genetic  perturbation  experiments.  Gustafsdottir  et  al.  (2013)  reported  that  the  Cell  painting  
assay  could  identify  cellular  phenotypes  and  cluster  compounds  with  similar  chemical  
structure  or  annotated  targets  based  on  the  cellular  profiles  111 .  Cell  painting  does  have  some  
limitations.  Singh  et  al.  (2015)  studied  the  morphological  profiles  of  RNAi-induced  
knockdown  in  U2OS  cell  line,  and  was  unable  to  group  cell  profiles  by  RNAi  targets  in  the  
same  gene  compared  to  different  genes.  The  cause  of  this  could  be  off-target  effects  112 ,  hence  
the  more  precise  suppression  technique,  CRISPR,  may  potentially  fix  this  problem,  and  is  a  




1.8.3  Single-cell  RNA  sequencing  
The  technology  of  scRNA-seq  enables  us  to  establish  the  transcriptional  profiles  of  individual  
cells  by  capturing  and  reading  the  cell’s  individual  mRNA  transcriptome  113 .  With  the  
development  of  technologies  such  as  microfluidics,  robotics,  and  reverse  emulsion  and  
hydrogel  droplets,  scRNA-seq  can  process  hundreds  of  thousands  of  cells  per  experiment  114 .  
The  methods  of  scRNA-seq  differ  in  whether  the  mRNAs  are  reverse  transcripted  to  
full-length  cDNA,  such  as  SMART-seq2  ( Switch  Mechanism  at  the  5'  End  of  RNA  Templates  
sequencing ) 115 ,  or  cDNA  with  a  unique  molecular  identifier  (UMI),  such  as  Drop-seq  116 .  
These  methods  have  been  integrated  into  platforms  such  as  SMART-seq2  (illumina)  and  10X  
Genomics  Chromium,  among  others.  Briefly,  in  the  droplet  based  system  used  by  the  10X  
Genomics  Chromium  platform,  a  single  cell  suspension  would  be  prepared,  and  then  the  cells  
are  individually  encapsulated  into  a  water-in-oil  droplet  together  with  a  gel  bead  which  is  
labeled  with  oligonucleotides.  The  oligonucleotide  consists  of  a  unique  barcode  for  each  cell  
(16  bp),  an  UMI  (8  bp),  sequencing  adapters,  and  an  anchored  oligo-dT.  Next,  reverse  
transcription,  cDNA  amplification  and  library  construction  occurs,  followed  by  next  
generation  sequencing  (NGS).  The  downstream  processing  with  the  data  generated  by  NGS  
involves  data  de-multiplexing,  alignment,  and  then  biological  data  interpretation,  which  
should  be  designed  specifically  117,118 .  scRNA-seq  gives  us  the  opportunity  to  study  
heterogeneity  in  a  whole  organism  and  investigate  the  differential  expression  of  genes  at  the 
cell  level.  For  example,  Kim  et  al.  (2015)  reported  a  subgroup  which  is  related  to  anti-cancer  
drug  resistance  from  tumor  cells  of  lung  adenocarcinoma  119 .  Smillie  et  al.  (2019)  also  
identified  51  cell  subgroups  in  human  colon  mucosa  from  patients  with  ulcerative  colitis  
versus  healthy  individuals  and  found  many  ulcerative  colitis  risk  genes  were  convergent  onto  
limited  sets  of  cell  types  and  pathways  120 .  Lukowski  et  al.  (2019)  identified  18  cell  types  by  
performing  scRNA-seq  on  20,  009  cells  from  the  human  retina  121 .  Patel  et  al.  (2020)  
identified  12  cell  populations  using  scRNA-seq  on  8,758  cells  from  human  TMCs  and  
neighboring  tissues  122 .  Single  cell  RNA-seq  is  a  powerful  tool  to  investigate  subtle  changes  
in  cell  transcription,  combined  with  cell  painting,  we  can  gain  a  novel  understanding  of  the  
morphological  and  transcriptional  changes  that  occur  as  a  result  of  Cas9-mediated  gene  
knockout  and  potentially  determine  a  causal  relationship  between  certain  genes  and  disease  




In  summary,  TMCs  are  vital  models  in  studying  the  disease  of  glaucoma.  Due  to  the  
difficulty  in  harvesting  human  TMCs  and  the  limitation  in  the  usage,  we  investigated  whether  
MSCs  could  acquire  TMCs  properties  in  response  to  the  combination  of  RA,  TGF-β2,  and  
BMP4.  Also,  we  firstly  utilised  novel  techniques  of  CRISPR,  CellPainting  and  scRNA-seq  
together  to  study  the  effects  of  IOP-associated  genes  in  human  primary  TMCs,  where  the  
morphological  and  transcriptome  profiles  illuminate  their  roles  in  the  pathogenesis  of  




2.  AIMS  AND  HYPOTHESIS  
  
2.1  Characterize  DP-MSCs  under  the  treatment  of  combination  of  transcription  
factors,  RA,  TGF-β2,  and  BMP4.   
Aim:   To  determine  whether  DP-MSCs  could  be  induced  to  exhibit  the  phenotypic  properties  
of  human  TMCs  through  the  exposure  of  the  transcription  factors  known  be  involved  in  the  
embryogenesis  of  the  anterior  segment;   
Hypothesis:  After  the  treatment  of  combination  of  transcription  factors,  RA,  TGF-β2,  and  
BMP4,  DP-MSCs  will  express  the  gene  markers  of  human  TMCs.  Also,  the  treated  
DM-MSCs  will  upregulate  the  expression  of  myocilin  under  the  presence  of  dexamethasone  
and  exhibit  contractile  properties.   
  
  
2.2  Morphological  and  genetic  profiles  of  CRISPR-induced  gene  knockout  in  
human  TMCs  
Aim ： To  use  Cell  Painting  and  scRNAseq  to  generate  morphological  and  transcriptome  
profiles  of  TMCs,  in  which  genes  implicated  in  IOP  variation  have  been  knocked  out  by  
CRISPR.  
Hypothesis:  That  the  morphological  and  transcriptional  profiles  of  TMC  knockout  lines  will  
indicate  how  that  gene  may  contribute  to  TM  dysfunction  in  POAG,  and  genes  involved  in  








3.  METHODS:  
3.1  Cell  culture:  
3.1.1  Cell  type  and  culture  medium:  
Primary  human  TMCs  were  isolated  from  patients  by  Dr.  Helena  Liang  in  the  Royal  
Victorian  Eye  and  Ear  Hospital  (Ethics  approved,  Ref.  13-1151H).  The  primary  human  TMCs  
were  cryopreserved  at  Passage  0  and  delivered  frozen.  These  TMCs  were  thawed  and  
cultured  in  Dulbecco’s  Modified  Eagle  Medium  (DMEM,  Gibco,  11965118)  with  10%  fetal  
bovine  serum  (FBS,  Gibco,  16000044),  and  supplemented  with  0.5%  antibiotic-antimycotic  
(Gibco,  15240-062).  Commercial  human  TMCs  were  bought  from  ScienCell  (Cat.  6590)  and  
cultured  in  trabecular  meshwork  cell  medium  (TMCM,  ScienCell,  6591).  Human  neonatal  
dermal  fibroblast  (HNDF,  Thermofisher,  C0045C),  HEK-293A  and  HEK-293FT  were  all  
cultured  in  DMEM  with  10%  FBS  supplement  and  1%  antibiotic-antimycotic.  Dental  pulp  
mesenchymal  stem  cells  (DP-MSCs,  Lonza,  PT-5025)  were  cultured  in  the  DP-MSC  culture  
medium  (Lonza,  PT-3005).  All  cell  lines  were  cultured  at  37℃  with  5%  CO 2   in  the  incubator.  
Each  fortnight  cell  lines  were  tested  for  mycoplasma  using  the  PCR  Mycoplasma  Test  Kit  
(PromoKine,  PK-CA91-1096).   
  
3.1.2.  Cell  Maintenance  and  Subculture  
To  maintain  TMCs  and  DP-MSCs,  the  culture  medium  was  changed  every  3  days  when  cells  
were  less  80%  confluent.  Once  the  confluence  reaches  80%,  the  medium  was  changed  every  
other  day  before  subculturing.  For  HNDF,  HEK-293A,  and  HEK-293FT,  the  medium  should  
be  changed  every  3  days  before  subculturing.  All  cell  lines  were  allowed  to  reach  ~90%  
confluence  in  vessels,  with  different  types  of  vessels  used  for  different  purposes  ( Table  3 ).   
For  subculturing,  cells  were  washed  twice  with  DPBS  (Gibco,  14190144)  and  then  incubated  
with  Trypsin/EDTA  (Gbico,  25200056)  at  37℃  with  5%  CO 2 .  For  TMCs,  the  concentration  
of  Trypsin/EDTA  is  0.05%,  diluted  in  DBPS.  For  DP-MSCs,  HNDF,  HEK-293A,  and  
HEK-293FT,  the  concentration  of  Trypsin/EDTA  is  0.25%.  After  2-3  minutes  of  
trypsinization  the  cells  should  round  up  and  detach  from  the  culture  surface.  The  vessel  may  
be  gently  tapped  to  assist  with  cell  detachment.  The  trypsin  is  then  neutralised  with  the  
culture  medium  (5X  volume  of  0.25%  Trypsin/EDTA)  or  Trypsin  Neutralizer  Solution  
20  
  
(Gbico,  R002100)  (2X  volume  of  0.25%  Trypsin/EDTA).  Cells  are  then  centrifuged  at  room  
temperature.  For  DP-MSCs,  220  x  g  for  5  minutes;  for  TMCs,  HNDF,  HEK-293A,  and  
HEK-293FT,  300  x  g  for  5  minutes.  After  aspirating  the  supernatant,  cells  would  be  
resuspended  in  the  culture  medium  and  cell  number  and  viability  would  be  determined  by  
hemocytometer.  To  obtain  a  clear  view  of  individual  cells  after  subculturing,  and  given  that  
the  cell  painting  and  phagocytosis  assays  require  a  low  confluence,  cells  were  seeded  at  a  
density  of  approximately  40%~50%.  The  optimal  seeding  number  of  different  cell  types  and  
corresponding  culture  vessels  are  listed  ( Table  3 ).   
  
3.1.3  Freezing  and  thawing  
The  procedure  for  freezing  cells  is  similar  to  subculture,  except  that  cells  are  resuspended  in  
cold  freezing  medium  (FBS  with  10%  DMSO  (Merck,  D2650)).  Generally,  one  cryovial  
contains  1ml  cell  suspension  with  1*10^6  cells.  Cryovials  are  then  stored  in  a  Mr.  Frosty  
container  (Thermo  Scientific,  5100-0001)  and  placed  at  -80°C  for  at  least  6  hrs.  These  
cryovials  are  transferred  to  liquid  nitrogen  the  next  day  for  long  term  storage.  To  quickly  
thaw  cells,  the  cryovials  are  half  immersed  in  a  37 °C  water  bath  on  a  floating  plate  for  less  
than  2  minutes,  then  cells  are  gently  resuspended  in  culture  medium  and  plated  into  
appropriate  cultureware.  The  culture  medium  should  be  changed  the  following  day  and  
regular  culture  procedures  followed.  
  
3.2  Characterization  of  the  trabecular  meshwork  cells  
3.2.1  Treatment  with  dexamethasone  in  TMCs  
TMCs  were  plated  out  in  6-well  plates  with/without  coverslips  (1.5*10 5   cells/well)  and  
allowed  to  adhere  overnight.  The  following  day,  TMCs  were  treated  with  different  
concentrations  of  dexamethasone  in  culture  medium  (Sigma-Aldrich,  D4902)  (100nM,  
500nM,  1μM,  2  μM,  5μM)  or  0.1%  ethanol  (EtOH;  vehicle  control),  which  was  continued  for  
three  days.  TMCs  cultured  without  coverslips  were  harvested  for  RNA  extraction  to  detect  
the  level  of  MYOC  mRNA,  and  TMCs  cultured  with  coverslips  were  fixed  in  4%  
paraformaldehyde  (Sigma-Aldrich,  441244)  for  immunocytochemistry.   
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Table  3:  The  use  of  different  culture  vessels  and  optimal  seeding  number  of  different  cell  lines  
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Culture  Vessel  Usage  






T-75  flask  
(Corning,  
430641U)  
Thaw,  expand,  and  
freeze  cells  
1  3  
T-25  flask  
(Corning,  430639)  
Thaw  and  freeze  cells  0.3  1  
6-well  Tissue  
Culture  treated  




with  glass  coverslips  
0.15  0.5  
24-well  Tissue  
Culture  treated  
plate  (Corning,  
3524)  
Lentivirus  transfection   0.03  /  
96-well  
Black/Clear 
Imaging  plate 
(Flacon,  
FAL353219)  
Cell  Painting  Assay  0.004  /  
96-well  




Phagocytosis  0.03  0.1  
10  mm  tissue  
treated  cell  culture  
dish  (Falcon,  
353003)  
Lentivirus  preparation  /  8  
  
  
3.2.2  RNA  extraction,  reverse  transcription  and  quantitative  real-time  PCR  
RNA  was  extracted  using  RNeasy  plus  micro  kit  (Qiagen,  74134)  following  the  supplied  
manufacturer’s  protocol.  Briefly,  cells  were  washed  once  using  DPBS  and  350μL  of  Buffer  
RLT  Plus  was  added  to  lyse  cells.  Cell  lysates  were  transferred  to  the  gDNA  Eliminator  spin  
column,  and  subsequently  transferred  to  an  RNeasy  spin  column  for  purification.  The  RNA  
was  eluted  in  30μL  of  RNase-free  water  and  the  concentration  was  measured  by  Nanodrop  
1000  (Thermo  Scientific).  
  
Reverse  transcription  was  performed  to  produce  cDNA  following  Qiagen’s  protocol.  Briefly,  
a  volume  of  thawed  RNA  corresponding  to  the  amount  of  cDNA  required  was  added  to  8  μL  
of  master  mix  and  RNase-free  water  was  added  up  to  a  volume  of  20  μL.  For  each  reaction  in  
the  master  mix,  2  μL  10*  Buffer  RT,  2  μL  dNTP  Mix  (5  mM  each  dNTP),  2  μL  Oligo  dT  
Random  Primer  9,  1  μL  RNase  inhibitor  (10  units/μL)  and  1  μL  Omniscript  Reverse  
Transcriptase  (4  units/μL)  was  added  and  subsequently  pipetted  into  individual  reaction  
tubes.  200  mg  of  RNA  was  added  per  reaction,  tubes  were  vortexed  for  less  than  5  seconds,  
spun  down  and  then  incubated  for  1  hour  at  37°C.  Finally,  the  cDNA  samples  were  placed  in  
ice  for  qPCR  analysis  or  stored  at  -20°C.  
  
For  quantitative  real  time  PCR  reactions,  cDNA  samples  were  diluted  to  2  ng/μL  using  
nuclease-free  water.  qRT-PCR  was  performed  using  the  LightCycler  480  system  (Roche).  
TaqMan  Probe/primers  for  MYOC ,  EEF2  ( Eukaryotic  elongation  factor  2 )  were  selected.  For  
each  well,  cDNA  (5  μL)  was  added  to  15  μL  of  TaqMan  PCR  mix  (10  μL  2X  TaqMan  Master  
Mix,  1  μL  20X  probe/primer  mix,  4  μL  nuclease-free  water).  20  μL  of  total  reaction  was  
added  to  each  well  of  a  96-well  PCR  plate,  and  each  sample  for  each  gene  had  a  duplicate  in  
the  96-well  plate.  qRT-PCR  was  performed  using  the  following  program:  initial  polymerase  
activation  for  10  minutes  at  95°C  and  50  cycles  of  amplification  (denaturation  for  15  seconds  
at  95°C,  annealing  and  extension  for  1  minute  at  60°C).  The  Ct  value  of  each  gene  for  each  
sample  was  calculated  as  the  mean  value  of  the  Ct  values  of  the  duplicates.   Relative  gene  
expression  analysis  was  performed  using  the  2 -ΔΔCt   method  as  the  relative  expression  of  target  




3.2.3  Immunofluorescent  staining  of  TMCs  
For  immunofluorescence  experiments,  TMCs  were  fixed  in  4%  paraformaldehyde  for  20  
minutes  and  then  washed  with  phosphate-buffered  saline  (PBS,  0.01M)  three  times.  Then  the  
cells  were  permeabilized  by  0.1%  solution  of  Triton  X-100  (Sigma,  T8787)  for  10  minutes  
with  agitation  and  washed  with  PBS  three  times  again.  Cells  were  blocked  in  PBS  containing  
10%  FBS  for  at  least  30  minutes  at  room  temperature.  Then  the  cells  were  incubated  with  the  
primary  antibodies  ( Table  4 )  at  4°C  overnight.  The  following  day,  cells  were  washed  with  
PBS  four  times  with  agitation  and  then  incubated  with  corresponding  secondary  antibodies  
with  agitation  for  2  hours  in  darkness  at  room  temperature,  followed  with  
4,6-diamidino-2-phenylindole  (DAPI,  1μg/ml)  (Merck,  10236276001 )  for  10  minutes.  Cells  
were  then  washed  with  PBS  four  times.  The  coverslips  were  mounted  onto  glass  slides  with  
mounting  media  (Dako,  S202380-2),  and  allowed  to  dry  overnight  before  sealing  with  nail  
polish.  Images  were  taken  by  the  fluorescent  microscope  olympus  BX53.   
  
  
Table  4:  List  of  antibod ies  used  
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Antibody  Company  Catalogue  
Number  
Working  
Concentration  &  
Dilution  ratio  
Host  Species  
Reactivity  
myocilin  Cloud-Clone  
Corp.  
PAH586Hu01  5  μg/ml   
1:40  
Rabbit  Homo  sapiens  
Caveolin-1  Cell  Signaling  3238S  1:400  Rabbit  Homo  sapiens  
TIMP3  Abcam  ab39184  5  μg/ml  
1:200  
Rabbit  Homo  sapiens  
Alexa  Fluor  488  
goat  anti-rabbit  
ThermoFisher  A11034  2  μg/ml  
1:1000  
Goat  Rabbit  
Alexa  Fluor  555  
donkey  anti-rabbit   
Abcam  ab150074  2  μg/ml  
1:1000  
Donkey  Rabbit  
  
  
3.2.4  Phagocytosis  assay  
In  the  phagocytosis  experiment,  TMCs,  HNDF,  and  HEK293A  were  seeded  into  a  96-well  
black/clear  bottom  plate.  Macrophages  were  also  used  as  a  positive  control,  which  were  a  gift  
from  Peng  Chen  at  the  Menzies  Institute  for  Medical  Research.  The  cells  were  incubated  with  
100  μL  1mg/ml  S.  aureus  pHrodo  red  particles  (ThermoFisher  Scientific,  A10010)  for  2  
hours  at  37 °C.  Then  each  well  was  washed  with  DPBS  (Gibco,  14040133)  three  times  gently,  
no  final  aspiration.  Plate  was  observed  under  the  live  cell  fluorescent  microscope  Nikon  Ti2.   
  
3.3  Effects  of  transcription  factors  in  DP-MSC  
3.3.1  Treatment  with  the  combination  of  transcription  factors  RA,  TGF-β2,  BMP4  and  
dexamethasone  in  DP-MSCs.   
For  this  treatment,  the  concentrations  of  each  growth  factor  were  selected  by  previous  study  
(McDonald,N.L.,  2015).  Prior  to  adding  into  the  culture  media,  retinoic  acid  (RA,  Sigma,  
R2625)  was  diluted  to  1mM  in  DMSO,  recombinant  human  transforming  growth  factor-β2  
(TGF-β2,  Invitrogen,  PHG9114)  and  bone  morphogenetic  protein  4  (BMP4,  Invitrogen,  
PHC9534)  were  diluted  to  10μg/mL  in  0.1%  BSA/HBSS  (Bovine  Serum  Albumin,  
Invitrogen,  A8806;  HBSS,  Gibco,  14025134).  Cells  were  treated  with  the  culture  medium  
containing  0.1μM  RA,  5ng/mL  TGF-β2,  and  10ng/mL  BMP4  or  vehicle  control  (DMSO  and 
0.1%  BSA/HBSS)  for  48  hours.  This  was  followed  by  a  medium  change  with  the  same  
concentrations  of  growth  factors  or  vehicle,  with  the  addition  of  1μM  dexamethasone  or  0.1%  
ethanol  for  another  24  hrs.  After  three  days  treatment,  DP-MSCs  were  harvested  for  RNA  
extraction  to  detect  the  mRNA  level  of  myocilin  intracellularly  and  conditioned  medium  was  
collected  for  enzyme-linked  immunosorbent  assay  to  assess  extracellular  myocilin  levels.  The  
experiment  was  repeated  three  times  from  passage  4  to  passage  6.  
  
3.3.2  Quantitative  PCR  (qPCR)  of  candidate  genes  
The  procedure  for  qPCR  is  previously  described  in  chapter  3.2.2.  TaqMan  Probe/primers  for  
MYOC ,  MGP ,  FOXC1 ,  PITX2 ,  FOXC2 ,  PAWR ,  and  HPRT1  were  selected.  Relative  gene  
expression  analysis  was  performed  using  the  2 -ΔΔCt   method  as  the  relative  expression  of  target  




3.3.3  ELISA  (Enzyme-linked  immunosorbent  assay)  
To  determine  whether  dexamethasone  influences  the  expression  level  of  MYOC  secreted  
extracellularly,  ELISAs  were  performed  with  the  Cloud-Clone  kit  according  to  manufacturer  
instructions  (Cloud-Clone  Corp.  USA,  SEH586Hu ).  Briefly,  the  standard  solution  was  diluted  
(concentration  gradient:  50  ng/mL,  25  ng/mL,  12.5  ng/mL,  6.25  ng/mL,  3.12  ng/mL,  1.56  
ng/mL,  0.78  ng/mL)  and  100  μL  was  added  to  each  well.  Then  100  μL  samples  of  culture  
supernatant  from  the  cells  or  an  equal  volume  of  culture  medium  for  blank  samples  was  
added.  Then  the  plate  was  incubated  at  37°C  for  one  hour  and  the  liquid  was  removed.  100  
μL  Detection  Reagent  A  was  added  to  each  well  and  the  plate  was  incubated  for  another  hour  
at  37°C.  Each  well  of  the  plate  was  washed  with  Wash  Solution  and  dried  on  the  absorbent  
paper.  100  μL  Detection  Reagent  B  was  added  to  each  well  and  the  plate  was  incubated  at  
37°C  for  30  minutes.  The  plate  was  then  washed  with  Wash  Solution  five  times.  Then  90  μL  
of  Substrate  Solution  was  added  to  each  well  and  incubated  for  20  minutes  at  37°C.  50  μL  
Stop  Solution  was  added  to  each  well  to  terminate  the  color  reaction.  The  absorbance  of  each  
well  was  measured  at  450  nm  using  a  microplate  reader  (Tecan  Spark).   
   
3.3.4  Collagen  contraction  assay  
In  this  experiment,  DP-MSCs  that  had  undergone  five  days  treatment  with  the  combination  of  
the  growth  factors,  RA,  TGF-β2,  BMP4  were  investigated,  together  with  HNDF  and  TMCs  
as  positive  controls.  Collagen  gel  contraction  assay  was  performed  as  described  in  the  studies  
93,94 ,  with  some  modifications.  The  wells  of  24-well  culture  clusters  were  each  coated  with  
1%  BSA  at  37  °C  for  1  hour.  DP-MSCs,  HNDF  TMCs  were  trypsinized  and  resuspended  in  
culture  medium  at  a  density  of  2.2*10 6   cells/ml  without  or  with  10μM  Y-27632  ROCK  
inhibitor  (Sigma-Aldrich,  Y0503).  To  prepare  the  1.1  ml  collagen  gel  mixture,  700μl 
Collagen  type  I  (3mg/ml,  ThermoFisher,  A1048301),  110μl  10*DMEM  (Sigma,  D2429),  
110μl  10X  PBS,  17.5μl  1N  NaOH,  62.5μl  water  and  100μl  cells  suspension  were  mixed  in  an  
ice  bath  (final  concentration  of  collagen  type  I,  1.9mg/ml;  final  cell  density,  2*10 5   cells/ml).  
The  mixture  (0.5  mL)  was  added  to  each  well  of  the  BSA  coated  culture  clusters,  and  
collagen  gel  formation  was  induced  by  incubation  at  37°C  for  90  minutes.  Growth  medium  
(0.5mL),  without  or  with  10μM  Y-27632,  was  then  added  on  top  of  the  collagen  gels.  After  1  
hour,  the  gels  were  freed  from  the  wall  of  the  culture  wells  with  the  use  of  a  micro  spatula.  
Photos  were  taken  every  24  hours  up  to  72  hours  and  the  area  of  each  collagen  gel  was  
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measured  using  ImageJ.  The  extent  of  contraction  of  the  collagen  gels  was  calculated  by  
comparing  the  decrease  in  gel  diameter  with  the  initial  diameter.  Each  experiment  was  
performed  in  quadruplicate  and  was  repeated  three  times.  
  
3.3.5  Statistical  analysis  for  qPCR,  ELISA  and  collagen  contraction  assay  
Raw  data  from  each  experiment  was  collated  in  Microsoft  Excel  and  statistical  analysis  was  
performed  via  GraphPad  Prism  V6.01.  TMCs  with  dexamethasone  treatment  were  analyzed  
using  a  one-way  Analysis  of  Variance  (ANOVA).  DP-MSCs  with  growth  factors  and  
dexamethasone  were  analyzed  using  a  two-way  ANOVA.  Significant  results  were  
differentiated  using  Tukey’s  post-hoc  test.  All  data  are  represented  as  mean  +/-  standard  
deviation  (SD).  Significant  results  are  defined  as  *p<0.05;  **p<0.01;  ***p<0.001,  and  
****p<0.0001.  
  
3.4  CRISPR-induced  gene  knockout  in  primary  human  TMCs  
The  gene  knockout  procedure  followed  the  method  of  modified  CRISPR  droplet  sequencing  
(CROP-seq)  123 .  Briefly,  cells  were  transfected  with  lentivirus  containing  the  CRISPR  system  
in  separate  wells  for  each  target  gene  (Arrayed  CRISPR  screen).  After  antibiotic  selection  
and  recovery  in  the  culture  medium,  cells  were  harvested  for  cell  painting  and  scRNA-seq  
( Fig.  6 ).  In  scRNA-seq,  the  CROP-seq  sgRNA  was  detectable  and  unique  in  each  well,  that  is  
we  were  able  to  use  the  sgRNA  as  the  tag  to  identify  which  well  the  cell  came  from  when  we  
pooled  all  cells  together.  
  




3.4.1  Cloning  and  validation  of  the  single-vector  CROPseq  system  
The  cloning  work  to  produce  CROP-seq  plasmids  was  done  by  Dr.  Sandy  Hung.  To  generate  
a  single-vector  system  CROPseq  plasmid  to  express  both  SpCas9  and  
sgRNA(CROPseq-EFS-SpCas9-P2A-EGFP;  Addgene  #99248),  the  EF1a  promoter  in  the  
CROPseq-Guide-Puro  124   (supplied  by  Christoph  Bock;  Addgene  plasmid  #  86708)  was  
replaced  with  the  EFS  promoter  to  drive  the  expression  of  SpCas9  using  the  Gibson  
Assembly  method  (NEBuilder  HiFi  DNA  Assembly  master  mix;  NEB).  The  
EFS-SpCas9-P2A  fragment  was  amplified  from  lentiCRISPRv2  125   (a  gift  from  Feng  Zhang;  
Addgene  plasmid  #  52961)  using  Q5  high-fidelity  DNA  polymerase  (NEB).  Puromycin  
resistance  gene  was  then  subsequently  replaced  with  EGFP  using  a  amplified  fragment  from  
the  pMLS-SV40-EGFP  plasmid  126   (a  gift  from  Stanley  Qi  &  Jonathan  Weissma;  Addgene  
plasmid  #  46919).   
  
The  expression  and  activity  of  the  single-vector  CROPseq  plasmid  was  tested  by  cloning  in  a  
sgRNA  targeting  the  DNMT3B  (sgRNA  sequence:  
  CAGGATTGGGGGCGAGTCGG)  127   or  LacZ  control  gene  (sgRNA  sequence:  
TGCGAATACGCCCACGCGAT)  128   using  Gibson  Assembly  method  and  transformed  into  
NEBStable  bacteria  (NEB)  as  outlined  in  Datlinger  et  al.  129   and  tested  in  HEK293A  cells  
(Life  Technologies).  EGFP  expression  was  visualised  using  the  Eclipse  Ti-E  inverted  
fluorescence  microscope  (Nikon).  Cleavage  activity  of  the  SpCas9  was  measured  through  the  
indel  formation  using  SURVEYOR  assay  (Integrated  DNA  Technologies).  Briefly,  genomic  
DNA  was  extracted  (QIAamp  DNA  mini  kit;  Qiagen)  from  HEK293A  cells  transfected  with  
CROPseq-EFS-SpCas9-P2A-EGFP  DNMT3B  sgRNA  plasmid  using  Fugene  HD  (Promega).  
PCR  fragment  for  SURVEYOR  assay  was  amplified  using  Q5  high-fidelity  polymerase  using  
the  primers  F:  5`-CAAGAGCATCACCCTAAGAATGC-3`  and  R:  
  5`-GTTGTCAGAGACTCTCCCCAAAG-3`  from  Datlinger  el  al.  130 .  Q5  PCR  conditions  
were  as  of  manufacturer’s  protocol  with  the  following  thermocycling  conditions:  98°C  30  
secs;  35  cycles  of  98°C  10  secs,  71°C  30  secs,  72°C  15  secs;  72°C  2  mins.  PCR  products  
were  gel  purified  using  the  QIAquick  gel  extraction  kit  (Qiagen).  200ng  of  purified  PCR  




3.4.2  Confirmation  of  sgRNA  sequence  via  Sanger  sequencing  
In  total,  134  sgRNAs  sequences  were  designed  by  Prof.  Alex  Hewitt  to  generate  the  67  
trabecular  meshwork  cell  lines  (124  sgRNAs  for  62  genes  and  10  sgRNAs  for  human  
non-targeting  control,  2  sgRNAs  for  each  cell  line)  ( Table  5 ,  Appendix.  Table  2).  Each  of  the  
sgRNAs  was  cloned  into  CROPseq-Guide-pEFS-SpCas9-p2a-puro  backbone  (Addgene:  
#99248)  by  Dr.  Sandy  Hung.  The  sequences  of  all  sgRNAs  templates  were  confirmed  by  
in-house  Sanger  sequencing.  Firstly,  each  template  was  amplified  by  the  BigDye  Terminator  
Cycle  v3.1  Sequencing  kit  (Applied  Biosystems,  4337454).  The  10  μl  reaction  system  
contained  1  μl  template,  1  μl  10μM  primer,  0.25  μl  Reaction  Mix,  1.75  μl  5X  Sequencing  
Buffer,  and  6  μl  nuclease-free  water.  Cycling  was  performed  using  the  following  program:  
initial  polymerase  activation  for  1  minute  at  96°C  and  25  cycles  of  amplification  
(denaturation  for  10  seconds  at  96°C,  annealing  for  5  seconds  at  50°C,  and  extension  for  4  
minutes  at  60°C),  then  held  at  15°C.  Samples  were  purified  with  the  CleanSEQ  kit  (Beckman  
Coulter,  A29151)  following  the  Agencourt  CleanSEQ  Dye-Terminator  Removal  protocol. 
Briefly,  10  μl  of  vortexed  CleanSEQ  reagent  and  42  μl  of  85%  ethanol  was  added  to  each  10  
μl  sample  and  gently  mixed.  The  sample  was  placed  on  the  96-well  magnetic  plate  for  3-5  
minutes  until  the  magnetic  beads  formed  a  ring  and  the  solution  was  clear.  The  supernatant  
was  removed  and  samples  were  washed  twice  with  100  μl  85%  ethanol  with  30  seconds  
incubation,  and  then  air  dried  for  five  minutes.  Lastly,  30  μl  nuclease-free  water  was  added  to  
each  sample  and  incubated  for  3-5  minutes  on  the  magnetic  tray  to  elute  the  purified  DNA.  
Next,  15  μl  of  purified  cycle  sequencing  product  was  added  to  the  sequencing  plate,  then  
denatured  by  incubating  at  95°C  for  5  minutes  (no  heat  on  lid).  The  plate  was  loaded  into  the  
sequencer  (Genetic  Analyzer  3500,  Applied  Biosystems)  and  the  default  program  for  850  bp  
length  of  DNA  was  used.  Finally,  the  online  alignment  tool  MAFFT  (version  7)  was  used  to  
confirm  whether  the  sequences  of  all  the  134  sgRNAs  were  matched  with  reference  
sequences.   
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Table  5:  CRISPR/Cas9  sgRNAs  designed  to  target  genes  at  loci  previously  associated  
with  variation  in  intraocular  pressure.   
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GUIDES_sg001 GTTGACTGGGAGAGAACACG  ABCA1  46  ABC_tran  0.707186352 
GUIDES_sg002 GTGTTCTAAAAGAGAAACAC  ABCA1  50  -  0.684107302 
GUIDES_sg003 GTGCAGTGTCTCTCCTACAC  ADAMTS6  28  -  0.720054847 
GUIDES_sg004 ACCAGTCATGTCCACCACAG  ADAMTS6  26  -  0.71972146 
GUIDES_sg005 CAAGGGTAAAAAGCCCCCCG  AFAP1  16  -  0.759587174 
GUIDES_sg006 GGAAAGAAAAGACCTTCGAG  AFAP1  17  -  0.753862205 
GUIDES_sg007 CAACTATAACGTCAGCCCAG  ALDH9A1  10  Aldedh  0.764185557 
GUIDES_sg008 TATGAACAATGCTGTAAAGG  ALDH9A1  6  Aldedh  0.704113168 
GUIDES_sg009 GTGCTGTGAGCTGGGAAGTG  ANAPC1  39  -  0.69840945 
GUIDES_sg010 ATGGCTCTTCCTGTAGGACG  ANAPC1  27  -  0.641611628 
GUIDES_sg011  CCCCAGCCAATATTCACCGG  ANGPT1  9  Fibrinogen_C  0.666179972 
GUIDES_sg012 AATATGGATGTCAATGGGGG  ANGPT1  8  Fibrinogen_C  0.630390739 
GUIDES_sg013 TAACGTGTAGATGCCATTCG  ANGPT2  5  Fibrinogen_C  0.692502215 
GUIDES_sg014 TGTGACATGGAAGCTGGAGG  ANGPT2  6  Fibrinogen_C  0.647042655 
GUIDES_sg015 ACTCGCTCTCAGGTTCCAGG  ANGPTL2  5  Fibrinogen_C  0.761119961 
GUIDES_sg016 CACCAGCATGTCACGCACAG  ANGPTL2  2  RasGEF  0.753686491 
GUIDES_sg017 CTTTGTGGGAGAATCCACCA  ANKH  14  ANKH  0.705623542 
GUIDES_sg018 TGAGGGCGCATCTCACCGGG  ANKH  13  ANKH  0.671178514 
GUIDES_sg019 CTTCCGACATGCCCGCAACG  ANTXR1  10  Anth_Ig  0.66965417 
GUIDES_sg020 CAGAACTGGAGATAAAAGAG  ANTXR1  12  Anth_Ig  0.661995855 
GUIDES_sg021 CTGCTGGACCAGAAATTCGG  ARHGEF12 39  -  0.715629912 
GUIDES_sg022 TCTCTGGGGTCATAATCATG  ARHGEF12 38  -  0.682338139 
GUIDES_sg023 TACCAAATATGCCCCAACAG  ATXN2  21  -  0.746394842 
GUIDES_sg024 ATTACAGGACTATAGACATG  ATXN2  22  -  0.705381212 
GUIDES_sg025 ATGGGCCCAGGACTTCCAGG  BCAS3  35  -  0.763805308 
GUIDES_sg026 TGAACTGGATGAGATAACTG  BCAS3  36  -  0.749363581 
GUIDES_sg027 AGTTTTTAGGCTGAAACTGG  CAPZA1  6  F-actin_cap_A  0.671121892 
GUIDES_sg028 GGAATAATGGTCTTTCACAT  CAPZA1  5  F-actin_cap_A  0.61837895 
GUIDES_sg029 TAAACACCTCAACGATGACG  CAV1  3  Caveolin  0.697766064 
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GUIDES_sg030 TGGGGGCAAATACGTAGACT  CAV1  1  Caveolin  0.638532867 
GUIDES_sg031 GATGTGCAGACAGCTGAGGG  CAV2  23  Caveolin  0.699222046 
GUIDES_sg032 CGGCGTACTCGAGGCCGCTG  CAV2  22  Caveolin  0.674769146 
GUIDES_sg033 TCAGGAAGCCAAAGTCCCAG  CDH11  19  Cadherin  0.765145054 
GUIDES_sg034 GGATTGTGAATGATTTCAGG  CDH11  20  Cadherin  0.686839641 
GUIDES_sg035 GGGTTATCTCGTGTGCCAAG  COL24A1  60  COLFI  0.662833491 
GUIDES_sg036 GAAATTGCAGAAAACCTCAA  COL24A1  61  COLFI  0.614109727 
GUIDES_sg037 AAGCGGCCAGACTTCCTGCG  CTTNBP2  25  -  0.737788504 
GUIDES_sg038 GCCAGGTTGTCTTTTCACAG  CTTNBP2  24  -  0.682279464 
GUIDES_sg039 AACATTCCCAGCATGTACGG  DGKG  22  DAGK_acc  0.746132205 
GUIDES_sg040 GTACTTTGAATTTGGCACCT  DGKG  21  DAGK_acc  0.610555363 
GUIDES_sg041 GACCACAAATGAATGCCGGG  EFEMP1  9  EGF_CA  0.7383367 
GUIDES_sg042 TCACCACTTGGTATCCCTGG  EFEMP1  8  EGF_CA  0.711733541 
GUIDES_sg043 ACGCTCTCTTTATCAGACTG  EMCN  19  Endomucin  0.716120299 
GUIDES_sg044 GTTTTAGAAGGTGATGCATC  EMCN  15  Endomucin  0.500046723 
GUIDES_sg045 AGGACTCCCAGGGACACCTG  EMID1  11  Collagen  0.633805274 
GUIDES_sg046 GCTGCCCAGCAGAGCCTTGG  EMID1  13  Collagen  0.50154336 
GUIDES_sg047 GCAGTGGACCAATCCAGCTA  ETS1  13  Ets  0.590477455 
GUIDES_sg048 CACTAAAGAACAGCAACGAC  ETS1  8  SAM_PNT  0.507782957 
GUIDES_sg049 ATGTTCAGTTGTAGGCACAA  FBXO32  7  -  0.680491123 
GUIDES_sg050 AACTTGTCCGATGTTACCCA  FBXO32  8  -  0.665922839 
GUIDES_sg051 ACAGTTCAGAGAGTGACGTG  FER  26  Pkinase  0.744231001 
GUIDES_sg052 ATGTCTCGTCAAGAGGATGG  FER  25  Pkinase  0.666176654 
GUIDES_sg053 GCCTGCAGATTAGCCTCCAA  FERMT2  17  PH  0.635135622 
GUIDES_sg054 CTGAGGTTCATCTGATGAGC  FERMT2  15  PH  0.496718402 
GUIDES_sg055 GGAGTTCATCCTCAACAATG  FMNL2  23  FH2  0.656016612 
GUIDES_sg056 TTCACAAACCGGACAAAGAC  FMNL2  24  FH2  0.52306371 
GUIDES_sg057 TGTGTACACACTACAGCTGG  FNDC3B  31  fn3  0.726749897 
GUIDES_sg058 GCTCTTCCCAGTTCAGTACA  FNDC3B  30  fn3  0.69274705 
GUIDES_sg059 GCTGAGCAACAAGACAGAGG  GAS7  19  -  0.715444147 
GUIDES_sg060 GCTTGCGAAGGTCGGCAATG  GAS7  18  -  0.692490099 
GUIDES_sg061 GCCCACACTCTCCAAGCACA  GNB1L  3  -  0.656080017 
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GUIDES_sg062 GCAGGCTCCAGATGTGTACC  GNB1L  2  WD40  0.572759585 
GUIDES_sg063 TGAACAGAGAGACTTCTGAG  KALRN  59  PH  0.713929927 
GUIDES_sg064 CTTCCTGAGATACAGTGAGA  KALRN  56  RhoGEF  0.590046749 
GUIDES_sg065 TGATTACTGGAAGTACGGGG  KREMEN1  5  WSC  0.732200895 
GUIDES_sg066 TTACTGGTGCCAGTTAGAGG  KREMEN1  4  WSC  0.660612633 
GUIDES_sg067 CAGGGACTCGATGATCATGG  LMO7  34  LIM  0.767439497 
GUIDES_sg068 GATCCTGACTTCAGCTCCTG  LMO7  35  LIM  0.666458078 
GUIDES_sg069 CTTCGACGAGACCTCGAAGG  LMX1B  4  Homeobox  0.713403988 
GUIDES_sg070 GTGCAAGGGTGACTACGAGA  LMX1B  3  LIM  0.675803927 
GUIDES_sg071 ACGTCTCGGATGGTGCTGAG  ME3  18  Malic_M  0.711900963 
GUIDES_sg072 AGAGAAAGAAGGTGTACCGA  ME3  14  Malic_M  0.683948993 
GUIDES_sg073 TAGTACTTCCCATGTGCCAG  MECOM  24  -  0.69054325 
GUIDES_sg074 ACTGTGGCAAGATTTTTCCA  MECOM  20  zf-C2H2  0.638498746 
GUIDES_sg075 GGACTTCTGCTCAAAGAGGG  MYOF  56  -  0.689398449 
GUIDES_sg076 TGCATGGGTTGGTGAACCAG  MYOF  58  -  0.68114604 
GUIDES_sg077 AAAGGTACTCTGAAACATGG  PARD3B  24  -  0.748915706 
GUIDES_sg078 TGGTCTCTTTCTGGAGACAG  PARD3B  25  -  0.687131379 
GUIDES_sg079 TCTGGGAGATGAGCAAGCAG  PDE7B  11  PDEase_I  0.63710316 
GUIDES_sg080 TCTTTCTGTTGATTACAAAG  PDE7B  12  PDEase_I  0.626787508 
GUIDES_sg081 CGTGAGACTCCAGTCACAGG  PKHD1  20  -  0.721146822 
GUIDES_sg082 ATGGGATAGCCCCAAGCAGG  PKHD1  16  -  0.648027027 
GUIDES_sg083 TACTCAGGGGATCACCAGCG  PLEKHA7  28  -  0.733493753 
GUIDES_sg084 CCCCGAACTCTACAGCCCAG  PLEKHA7  25  -  0.727012157 
GUIDES_sg085 GCTGCCCACTGCATACACGA  PRSS23  3  Trypsin  0.707785666 
GUIDES_sg086 AACATCAGTGAAGTTATCCA  PRSS23  3  Trypsin  0.589826381 
GUIDES_sg087 CAGTGGTGTCGGGAACACCG  PTPRJ  26  Y_phosphatase  0.752294442 
GUIDES_sg088 GTTCGGTAAAGGTCCTTGTG  PTPRJ  24  Y_phosphatase  0.742428198 
GUIDES_sg089 TGGCAAAAAGGTTTCCATCG  RALGPS1  25  PH  0.63983389 
GUIDES_sg090 CGAAAGAAGATAATTACAAG  RALGPS1  11  RasGEF  0.632295378 
GUIDES_sg091 AGAGGTACCAGATGGGACTG  RUNX2  5  Runt  0.707376125 
GUIDES_sg092 CATGGCGGAAGCATTCTGGA  RUNX2  11  RunxI  0.681198759 
GUIDES_sg093 TGGAATTCCCTACCACAGCG  SPTBN1  36  PH  0.712246448 
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GUIDES_sg094 TCAGTCTTAACCATTCCCAT  SPTBN1  31  Spectrin  0.683179693 
GUIDES_sg095 GGGCTGGCTATGATAAACTG  TES  6  LIM  0.774116567 
GUIDES_sg096 CCATGAGTTGTCTCCCAGAG  TES  5  PET  0.735126362 
GUIDES_sg097 GAAGCTTCCGAGAGTCTCTG  TIMP3  3  TIMP  0.703685264 
GUIDES_sg098 CTATGATGGCAAGATGTACA  TIMP3  4  TIMP  0.591387438 
GUIDES_sg099 AGTCCTTGGATGTAAGAAAG  TMCO1  9  DUF841  0.652850785 
GUIDES_sg100 GAAACAATAACAGAGTCAGC  TMCO1  5  DUF841  0.622258097 
GUIDES_sg101 AGAGACTTTGAAGTGAACGA  TNS1  42  PTB  0.715095311 
GUIDES_sg102 CAGAAGGTGACAGTGTTGAG  TNS1  43  PTB  0.675343539 
GUIDES_sg103 GCCGACTGGTGACCTCATGG  TRIOBP  3  -  0.713915639 
GUIDES_sg104 GGGAGCAGGAGGCAGGAACG  TRIOBP  4  -  0.656603289 
GUIDES_sg105 TAAACCACTGGAGTTCACGG  TXNRD2  20  Pyr_redox_dim  0.785275668 
GUIDES_sg106 TCATCATTGCTACTGGAGGG  TXNRD2  8  Pyr_redox_2  0.706088692 
GUIDES_sg107 GGTGAAGCTCCTGATTGCAG  ZNF280D  27  -  0.700021186 
GUIDES_sg108 GAAGAAAGTAAAAGAAGTTG  ZNF280D  15  -  0.599965492 
GUIDES_sg109 ATGGAGTTCCGCGACCACGT  ABO  7  CDS  0.6563 
GUIDES_sg110  CCGGTCCCCAGCGTCACGCG  ABO  7  CDS  0.6687 
GUIDES_sg111  CCACCTGGTACATCGCCTCA  TEX41  2  TRANSCRIPT  0.6631 
GUIDES_sg112  AACTCAAGACATTGGAACCA  TEX41  5  TRANSCRIPT  0.6251 
GUIDES_sg113  AATGTGGTAGCCCAAGACAG  CYP1B1  5  p450  0.775320729 
GUIDES_sg114  GTGGCCACTGATCGGAAACG  CYP1B1  3  p450  0.726256031 
GUIDES_sg115  GCAAGCCATGAGCCTGTACG  FOXC1  1  -  0.747984594 
GUIDES_sg116  TCGTCGTCCCTGAGTCACGG  FOXC1  1  -  0.730741126 
GUIDES_sg117  GATTGTGGTGAACTTCCGTG  GMDS  8  Epimerase  0.727535334 
GUIDES_sg118  GTTGCAGAATGATGAGCCGG  GMDS  10  Epimerase  0.65599947 
GUIDES_sg119  CCTCCCGCACGCGCACACAG  LTBP2  35  EGF  0.755863507 
GUIDES_sg120 CAGGCAGACATAACCAGGCA  LTBP2  31  EGF_CA  0.708717 
GUIDES_sg121 GGTCATACTCAAAAACCTGG  MYOC  3  OLF  0.763937898 
GUIDES_sg122 ATGCCAGTATACCTTCAGTG  MYOC  1  -  0.722928246 
GUIDES_sg123 TCTTGCGAAGGAAGTCCAGA  TEK  17  Pkinase  0.627785812 




3.4.3  Lentivirus  preparation  
The  plasmids  containing  the  134  sgRNAs  were  transformed  into  E.  coli  bacteria  and  stored  in  
glycerol  stocks  by  Dr.  Sandy  Hung.  To  harvest  enough  plasmids,  the  E.  coli  bacteria  were  
streaked  out  on  LB  agar  plates  with  1%  ampicillin  and  incubated  at  37°C  for  24  hours.  A  
single  colony  was  picked  into  2-YT  broth  (Invitrogen,  22712-220)  and  incubated  at  30°C  for  
16  hours.  The  plasmids  were  harvested  using  Wizard  Plus  SV  Minipreps  DNA  Purification  
Systems  (Promega,  A1460)  following  manufacturer  instructions,  the  plasmid  DNA  was  
eluted  in  30  μl  of  nuclease-free  water  and  the  DNA  concentration  was  measured  by  Nanodrop  
1000  (Thermo  Scientific).  To  prepare  the  lentiviruses,  the  plasmids  were  then  transfected  into  
HEK  293FT  cells.  For  each  gene  knockout  cell  line,  the  plasmids  of  the  two  sgRNA  were  
combined  (5  μg  each),  together  with  10  μg  pCMV  ∆8.91,  and  1  μg  pMD2.G  in  2.5  ml  
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_0001  ACGGAGGCTAAGCGTCGCAA  -  -  -  -  
NonTargeting_Human 
_0002  CGCTTCCGCGGCCCGTTCAA  -  -  -  -  
NonTargeting_Human 
_0003  ATCGTTTCCGCTTAACGGCG  -  -  -  -  
NonTargeting_Human 
_0004  GTAGGCGCGCCGCTCTCTAC  -  -  -  -  
NonTargeting_Human 
_0005  CCATATCGGGGCGAGACATG  -  -  -  -  
NonTargeting_Human 
_0006  TACTAACGCCGCTCCTACAG  -  -  -  -  
NonTargeting_Human 
_0007  TGAGGATCATGTCGAGCGCC  -  -  -  -  
NonTargeting_Human 
_0008  GGGCCCGCATAGGATATCGC  -  -  -  -  
NonTargeting_Human 
_0009  TAGACAACCGCGGAGAATGC  -  -  -  -  
NonTargeting_Human 
_0010  ACGGGCGGCTATCGCTGACT  -  -  -  -   
  
Opti-mem  (Gibco,  31985088),  then  combined  with  another  2.5  ml  Opti-mem  containing  30  
μl  Lipofectamine  2000  (Invitrogen,  10000230649 ).  The  5ml  transfection  mixture  was  
incubated  at  room  temperature  for  10-20  minutes  before  being  added  to  8*10^6  HEK  293FT  
cells  in  a  10cm  tissue  culture  treated  petri  dish.  The  cells  were  incubated  at  37°C  for  5  hours,  
then  the  medium  was  replaced  with  8ml  of  culture  medium  and  incubated  at  37°C  for  48  
hours.  The  supernatant  was  collected  and  filtered  through  a  45  μm  filter  (Merck,  
SLHV033RS),  5X  PEG-IT  (System  Biosciences,  LV825A-1)  was  added  to  concentrate  the  
virus  and  the  solution  was  stored  at  4°C  for  48  hours.  Subsequently,  the  virus  suspension  was  
centrifuged  at  1500  x  g  for  30  minutes  and  the  supernatant  was  removed.  Each  virus  pellet  
was  resuspended  in  1  ml  Opti-mem  and  stored  in  -80°C.   
  
3.4.4  Lentivirus  transduction  and  puromycin  selection  in  TMCs  
TMCs  were  first  expanded  in  T-75  flasks  and  then  seeded  in  to  tissue  culture  treated  24  well  
plates  ( Table  3 ),  3.0*10^4  cells  per  well.  The  following  day,  50  μl  of  lentivirus  was  added  to  
the  0.5ml  culture  medium  containing  Lentiblast  (OZ  Bioscience,  LB01500,  Concentration:  
LentiblastA:  1:100,  LentiblastB:  1:100)  and  the  cells  were  incubated  at  37°C  for  72  hours.  
Cells  were  then  cultured  in  medium  containing  1  μg/ml  puromycin  (Gibco,  A11138-03)  for  
four  days,  changing  the  medium  after  two  days,  after  which  the  no  lentivirus  control  cells  had  
all  died.  The  cells  were  then  allowed  to  recover  in  regular  culture  medium  for  one  week,  with  
medium  changes  every  two  days.  The  virus  transduction  was  performed  as  triplicates  on  
different  days.   
  
3.5  Cell  Painting  Assay  
3.5.1  Cell  seeding  with  FACS   
For  each  group,  4.0*10^3  puromycin-selected  TMCs  were  seeded  to  96-well  plates  (Falcon,  
FAL353219)  by  fluorescence  activated  cell  sorting  (FACS)  supported  by  Dr.  Terry  Pinfold  at  
the  Menzies  Institute  for  Medical  Research.  Each  group  was  split  into  triplicates  in  the  
96-well  plate  randomly.  The  culture  medium  was  changed  the  next  day.  The  whole  
experiment  was  performed  in  three  batches  of  TMCs,  thus,  9  wells  of  cells  were  captured  for  
each  gene  knockout  group.  The  plate  layout  (the  metadata)  can  be  assessed  on  github:  




3.5.2  Staining  and  fixation  
TMCs  were  stained  and  fixed  48  hours  after  FACS.  Previously  described  Cell  Painting  
Protocol  110,111   was  followed,  and  the  concentration  of  each  stain  was  manually  confirmed  on  
a  pilot  plate  ( Table  6 ,  Fig.  7 ).  Firstly,  TMCs  were  incubated  in  culture  medium  containing  
500  nM  Mitotracker  (Invitrogen,  M22436)  and  30  μg/mL  Wheat  Germ  Agglutinin  (WGA) 
Alexa594  conjugate  (Invitrogen,  W11262)  for  30  minutes  at  37°C.  Then  TMCs  were  fixed  
with  4%  paraformaldehyde  at  room  temperature  for  20  minutes  and  washed  with  150  μl  of  
HBSS  (Gibco,  14025134).  Next,  TMCs  were  permeabilized  with  0.1%  solution  of  Triton  
X-100  (Sigma,  T8787)  for  20  minutes  and  washed  with  150  μl  HBSS  twice.  Lastly,  TMCs  
were  incubated  with  HBSS  staining  solution  containing  1%  BSA  (Merck,  A8806),  50  μg/ml  
ConcanavalinA  (Invitrogen,  C11252),  3  μM  Syto14  (Invitrogen,  S7576),  5  μg/ml  Hoechst  
(Invitrogen,  H3570),  and  1  unit/ml  Phalloidin  (Invitrogen,  A12381)  for  30  minutes  at  room  
temperature.  TMCs  were  washed  three  times  with  HBSS  without  final  aspiration  and  then  
sealed  with  parafilm.  All  96-well  plates  were  kept  at  4°C  in  the  dark  before  imaging.   
  
Table  6:  Cell  painting  components  
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Dye  Organelle  or  cellular  component  Channel  name  
Hoechst  33342 Nucleus  DNA  
Concanavalin  A  Endoplasmic  reticulum  ER  
Syto  14  Nucleoli,  cytoplasmic  RNA  RNA  
Phalloidin,  Wheat  germ  
agglutinin  
F-actin,  Golgi,  plasma  membrane  AGP  
MitoTracker  Mitochondria  Mito  
  




3.5.3  Automated  Image  acquisition  
Images  were  captured  at  20X  magnification  in  Phase  Gradient  Contrast  (PGC),  and  5  
fluorescent  channels,  DAPI  (385/465  nm),  AF488(470/517  nm),  AF514  (511/543  nm),  
AF594  (590/618  nm),  AF647  (625/668  nm)  on  ZEISS  Celldiscoverer  7  system.  In  each  well,  
25  sites  were  imaged,  with  autofocus  in  the  DAPI  channel  as  the  reference.  Raw  output  files  
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were  generated  in  “ czi ”  format,  and  were  processed  using  Split  Scenes  and  Image  Export  with  
Zen  Blue  (Version  3.0).  In  Image  Export ,  exporting  file  format  as  TIFF ,  ticking  the  modules  
of  Convert  to  8  bit ,  Original  Data  and  Shift  Pixel ,  Use  channel  names  and  Use  Full  Set  of  
Dimensions .   
  
3.5.4  Morphological  image  feature  extraction  
Version  3.1.9  of  CellProfiler  was  used  to  locate  and  segment  the  cells  for  single-cell  feature  
extraction.  The  pipelines  in  CellProfiler  were  set  up  to  correct  uneven  illumination,  flag  
aberrant  images  and  identify  the  nuclei  from  DAPI  channel  and  the  entire  cell  from  AF594  
channel  ( Fig.  8 ),  then  measure  the  features  of  the  size,  shape,  texture,  intensity,  and  the  local  
density  of  the  nuclei,  cell  and  cytoplasm.  
  
Figure  8:  Identifying  primary  objects  and  secondary  objects  in  Cellprofiler.  Scale  bar:  20  μm  
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3.5.4.1  Establishing  the  CellProfiler  pipeline   
The  pipelines  consist  of  three  parts:  illumination  correction,  quality  control  and  image  
analysis,  and  they  are  created  for  each  batch  of  hTMCs  
( https://github.com/PeterLu0403/CROP_seq_Cellpainting/upload/master/Pipelines ).  These  
pipelines  can  be  dragged  to  the  panel  of  the  CellProfiler  directly,  same  as  the  images  to  be  
analyzed.  The  metadata  should  be  extracted  from  the  image  name  using  regular  expression.  
E.g.  hTMC_B1_Plate2-Scene-0001-P1-B03-Image  Export-01_AF488_ORG.tif :  
(?P<Cell>.*)_(?P<Plate>.*)-Scene-(?P<Scene>[0-9]{4})-P(?P<Position>[0-9]*)-(?P<We 
ll>.{3})-(?P<general>.*)_(?P<Channeln>.*)_ORG.tif  
Illumination  correction  pipeline  is  to  improve  fluorescence  intensity  measurement.  For  each  
fluorescent  channel  in  each  batch  of  images,  the  calculation  was  based  on  all  images  across  
cycles  and  then  a  *.npy  file  was  generated  which  would  be  used  in  the  other  pipelines.  
Quality  control  pipeline  is  to  identify  and  exclude  aberrant  images  such  as  blurry  images  and  
debris,  and  a  properties  file  would  be  generated.  In  CellProfiler  Analyst  (Version  2.2.1),  the  
quality  control  features  and  corresponding  thresholds  were  then  selected  for  each  batch  of  
images.  In  the  last  pipeline  of  image  analysis,  blurry  and  saturated  images  were  able  to  be  
removed  by  setting  up  the  selected  quality  control  features  and  thresholds  in  the  modules  of  
MeasureImageQuality  and  FlagImages .  Uneven  illumination  was  then  corrected  with  the  
“npy”  file.  To  identify  the  cell  components,  the  nuclei  was  defined  as  the  primary  object,  the  
cell  body  was  defined  as  the  secondary  object,  and  the  cytoplasm  was  defined  as  the  tertiary  
object.  Subsequently,  the  features  of  size,  shape,  granularity,  colocalization,  local  density,  and  
textures  were  measured,  and  the  data  was  saved  in  the  database  of  SQLite.   
  
3.5.4.2  Configuration  of  CellProfiler  pipelines  on  the  Nectar  Cloud   
The  first  two  pipelines  of  illumination  correction  and  quality  control  were  performed  at  a  
desktop  workstation  (CPU:  Intel  Xeon  Gold  5122,  RAM:  128  GB).  The  Nectar  Cloud  ( The  
National  eResearch  Collaboration  Tools  and  Resources  project )  was  applied  to  process  the  
analysis  pipelines  and  in  8  instances,  and  the  c3xxlarge  flavor  (32  virtual  CPUs  and  64  GB  of  
RAM)  was  used.  The  image  analysis  outputs  a  set  of  SQLite  files.  The  protocol  describes  
how  to  set  up  virtual  machines,  install  CellProfiler  in  Linux,  and  run  a  batch  script  and  can  be  
accessed  on  github  




3.5.4.3  Add  metadata  and  merge  all  dataset  
The  software  of  R  (Version  3.6.3)  was  used  for  data  analysis.  First,  an  R  script  was  written  to  
add  metadata  to  each  dataset,  such  as  the  knockout  gene  in  each  well.  Then  the  datasets  for  
each  96-well  plates  were  all  merged  together  into  a  csv  file.  
  
3.5.5  Data  Preparation  
The  procedures  of  data  preparation  were  done  by  R  (Version  3.6.3)  were  described  in  
Caicedo,  et  al.  131 ,  which  included  feature  transformation,  normalization  and  batch-effect  
correction.  Firstly,  all  the  negative  controls  were  selected  to  explore  the  distribution  of  the  
features  and  the  batch  effects.  Two  transformation  methods  were  applied,  generalized  
logarithmic  function  132   and  Box-Cox  transformation  133 .  To  avoid  nonpositive  values,  
generalized  logarithmic  function  used  a  shrinkage  strategy  while  Box-Cox  transformation  
used  a  shift  strategy 131 .  The  Anderson-Darling  test  was  performed  to  evaluate  the  normality  
of  each  feature 134 .  Next,  the  value  of  each  feature  was  normalized  by  subtracting  the  median  
value  of  each  feature  from  the  control  group  and  dividing  by  the  corresponding  median  
absolute  deviation  (MAD)  *1.4826  in  each  plate,  respectively.  The  single-cell  data  was 
aggregated  by  the  median  value  of  each  well  to  create  profiles  of  each  replicate.  The  
Spearman’s  correlation  was  calculated  for  all  replicates  within  a  plate  and  across  different  
plates.  The  replicates  are  selected  with  Spearman’s  correlation  score  >  0.2.   
  
3.5.6  Data  analysis  
All  gene  knockout  groups  underwent  hierarchical  clustering  and  were  plotted  as  a  cluster  tree.  
The  optimal  number  of  clusters  was  determined  by  the  silhouette  method.  To  annotate  each  of  
the  clusters,  the  top  features  and  tail  features  were  extracted.   
  
3.6  Single-cell  RNA  sequencing   
3.6.1  Chromium  Processing  
The  cells  recovered  in  normal  culture  medium  in  3.4.3  were  taken  to  Garvan-Weizmann  
Centre  for  Cellular  Genomics  for  single-cell  RNA  sequencing.  Single-cell  suspensions  were  
prepared  following  the  subculture  procedure  in  3.1.2.  The  cells  from  different  wells  were  
pooled,  centrifuged  and  resuspended  in  DPBS  containing  1%  BSA  (Sigma-Aldrich,  
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A8806-5G),  and  filtered  by  37  μm  strainer  (STEMCELL,  27215).  The  estimated  number  of  
cells  in  each  well  in  the  Chromium  chip  was  optimized  to  capture  about  16,000  cells.  The  
Chromium  library  was  then  generated  following  the  protocol  of  the  Chromium  Single  Cell  3’  
v2  Library  (10X  Genomics)  by  the  technicians  in  Garvan  Institute.  Briefly,  individual  cells  
were  allocated  into  nanoliter-scale  Gel  Bead-in-EMulsions,  in  which  the  bead  carries  the  
primers  containing  a  read  1  primer  sequence,  a  16  nt  10x  barcode,  a  10  nt  Unique  Molecular  
Identifier,  and  a  poly-dT  primer  sequence.  A  barcoded,  full-length  cDNA  was  produced  from  
each  poly-adenylated  mRNA  after  incubation  with  the  Gel  Bead-in-EMulsions.  Then  all  the  
cDNAs  were  pooled  and  amplified  by  PCR.  In  the  library  construction,  P5,  P7,  a  sample  
index,  and  read  2  primer  sequences  were  added  to  each  of  the  cDNA  by  End  Repair,  
A-tailing,  Adaptor  Ligation,  and  PCR.  The  region  of  P5  and  P7  allowed  the  library  fragment  
to  attach  to  the  flow  cell  surface  during  the  sequencing.  Read  1  and  read  2  sequences  are  
standard  Illumina  sequencing  primer  sites  used  in  paired-end  sequencing.  Then  part  of  the  
library  samples  were  sequenced  on  an  Illumina  NovaSeq  6000  system  using  the  S4  flowcell  
with  read  depth  of  approximately  84000  reads  per  cell.  The  rest  of  the  library  samples  after  
the  NovaSeq  procedure  were  used  to  amplify  the  sgRNA  sequences  for  enriched  
MiSeq-based  sequencing.   
  
3.6.2  Computational  analysis  of  single  cell  sequencing  data  
The  first  step  of  single  cell  RNA-seq  mapping  was  performed  by  the  service  provider,  
Garvan-Weizmann  Centre  for  Cellular  Genomics.  The  library  was  mapped  to  the  GRCH38  
Homo  sapiens  genome,  then  the  resulting  mapped  counts  between  all  samples  were  
depth-equalized  via  the  cellranger  aggr  pipeline.  Peter  Tran  performed  the  MiSeq-based  
sequencing,  and  Anne  Senabouth  from  Garvan  built  up  the  repository  for  the  processing  and  
analysis  of  single-cell  RNA-seq  data  ( https://github.com/powellgenomicslab/CROP-seq ).  In  
the  repository,  our  designed  gRNAs  are  assigned  to  their  respective  cells.Then  the  
scRNA-seq  data  was  loaded  into  R  via  the  Seurat  package  (Version  3.0),  and  SCTransform  
function  was  used  to  normalise  the  data.  All  cells  targeted  by  sgRNAs  were  visualised  in  a  
uniform  manifold  approximation  and  projection  (UMAP)  plot  and  were  clustered  with  the  
Louvain  method .  The  differentially  expressed  genes  (DEGs)  of  each  gene  knockout  group  
were  selected  with  log2  fold  change  >  2  compared  to  the  human  non  targeting  controls.  Then  
a  hierarchical  clustering  was  performed  on  the  subset  of  all  DEGs  of  all  gene  knockout  
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groups.  The  optimal  number  of  clusters  was  determined  by  the  silhouette  method.  DEGs  to  
the  human  non  targeting  controls  were  selected  to  present  each  cluster.    
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4.  RESULTS:  Characterization  of  human  trabecular  meshwork  cells  
4.1  Dexamethasone  induced  myocilin  secretion  assay  in  trabecular  meshwork  
cells  
The  commercial  TMCs  were  treated  with  different  concentrations  of  dexamethasone  (500  
nM,  1  μM,  2  μM,  and  vehicle  control )  for  3  days  (n  =  3),  after  which  RNA  was  extracted  for  
RT-PCR,  supernatant  was  collected  for  ELISA  and  cells  underwent  immunohistochemistry.  
In  RT-PCR  experiments,  the  expression  of  housekeeping  genes  was  firstly  assessed.  
Housekeeping  genes  were  cellular  maintenance  genes  which  regulate  basic  cellular  functions,  
and  they  would  not  change  their  expression  levels  across  groups  with  different  treatments.  
Therefore,  housekeeping  genes  were  involved  in  RT-PCR  to  act  as  internal  controls  for  gene  
expression.  The  expression  of  four  potential  housekeeping  genes  was  assessed  and  EEF2  
showed  the  most  consistent  expression  in  human  primary  TMCs,  as  demonstrated  by  the  
standard  deviation  in  the  fold  change  ( EEF2 ,  0.41;  HPRT,  0.42;  18sRNA ,  0.86  and  ACTB,  
0.91,  Fig.  9 A).  Thus,  EEF2  was  selected  as  the  housekeeping  gene.  No  MYOC  RNA  was  
detected  in  this  commercial  TMCs.  In  contrast,  the  expression  of  MYOC  was  upregulated  (8  
fold)  under  the  treatment  of  dexamethasone  (1  μM )  in  our  human  primary  TMCs  ( Fig.  9 B),  
and  the  extracellular  concentration  of  myocilin  measured  by  ELISA  was  also  increased  1.015  
ng/ml  ( Fig.  9 C).  Immunohistochemistry  labelling  demonstrated  that  the  intensity  of  the  
myocilin  in  the  dexamethasone  treated  primary  TMCs  ( Fig.  9 E)  was  stronger  than  the  vehicle  
control  TMCs  ( Fig.  9 D).  As  a  result,  the  primary  TMCs  were  used  in  our  next  experiment 
rather  than  the  commercial  TMCs.  The  expression  of  MYOC  following  dexamethasone  was  
assessed  by  immunocytochemistry  in  all  CROP-seq  knock-out  lines.  The  mean  intensity  of  
myocilin  for  each  cell  was  measured  and  normalized  to  mean  intensity  of  the  cell  nuclei.  For  
each  gene  knockout  group,  the  normalized  intensity  of  myocilin  was  slightly  increased  after  
the  dexamethasone  treatment  ( Fig.  10 ).  
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Figure  9:  Characterisation  of  TMCs:  A)  Assessment  of  housekeeping  gene  in  human  TMCs,  
expression  level  was  normalized  to  each  housekeeping  gene  without  the  dexamethasone  
treatment;  B)  Relative  expression  of  MYOC  with/without  the  treatment  of  dexamethasone  
normalized  to  EEF2;  C)  Secreted  myocilin  concentration  by  ELISA;  D)  Immunostaining  of  
myocilin  in  primary  TMCs  without  dexamethasone  treatment;  E)  Immunostaining  of  myocilin  
in  primary  TMCs  with  dexamethasone  treatment;  F)  Immunostaining  of  caveolin-1  in  
primary  TMCs;  G)  Immunostaining  of  TIMP3  in  primary  TMCs.  Scale  bar:  20  μm.   
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4.2  Evaluation  of  cell  markers  of  trabecular  meshwork  cells  
Primary  human  TMCs  and  human  neonatal  dermal  fibroblast  were  assayed  by  qRT-PCR  and  
immunocytochemistry  for  their  expression  of  TMC  markers.  The  expression  of  AQP1,  
CHI3L1,  LMX1B,  MGP,  MMP3,  TIMP2,  PITX2,  FOXC1,  FOXC2,  PAWR  were  all  detected  in  
TMCs,  and  their  expression  levels  varied  from  TMCs  to  fibroblast.  The  expression  levels  of  
AQP1,  CHI3L1,  and  PAWR  did  not  show  significant  difference  between  TMCs  and  fibroblast 
( Fig.  11 A,  B,  G).  LMX1B,  MGP,  PITX2,  FOXC1  and  FOXC2  were  expressed  significantly  
higher  in  TMCs  than  those  in  fibroblast  ( Fig.  11 C,  D,  G,  H,  I),  while  MMP3  and  TIMP2  were  





Figure  11:  TMC  markers  in  TMCs  and  human  natal  dermal  fibroblast  by  qRT-PCR.  A)-J):  
Relative  expressions  of  AQP1,  CHI3L1,  LMX1B,  MGP,  MMP3,  TIMP2,  PITX2,  FOXC1,  







4.3  Phagocytic  function  in  trabecular  meshwork  cells.  
pHrodo  bioparticles  were  used  to  measure  phagocytosis  activity  in  cell  culture.  The  particles  
emit  fluorescence  when  phagocytosed  and  transported  to  acidic  subcellular  structures.  After  2  
hours  of  incubation  with  the  pHrodo  red  bioparticles  at  37 °C,  our  primary  TMCs  show  
phagocytic  ability  ( Fig.  12 A)  that  is  stronger  than  the  fibroblast  ( Fig.  12 B),  but  weaker  than  
the  HEK  and  macrophages  ( Fig.  12 C,  D).  
  
Figure  12:  Phagocytosis  assay  using  pHrodo  bioparticles  (Red).  A)  TMCs,  B)  fibroblast  ,  C)  
HEK  293A,  D)  Macrophage.  Scale  bar:  20  μm.  
  
  
   
47  
  
5.  RESULTS:  Differentiation  of  TMCs  from  mesenchymal  cells  
5.1  Effects  of  combination  of  retinoic  acid  (RA),  transforming  growth  factor  β-2  
(TGF-β2),  and  bone  morphogenetic  protein  4  (BMP4)  in  dental  pulp  
mesenchymal  stem  cells  (DP-MSCs)  
In  previous  work  from  the  laboratory  135 ,  DP-MSCs  were  treated  with  different  combinations  
of  RA,  TGF-β2,  and  BMP4,  and  three  treatment  regimens  were  designed.  T1:  all  growth  
factors  were  applied  for  five  days;  T2:  TGF-β2  were  applied  for  the  first  2  days,  then  RA  and  
BMP4  were  applied  for  the  last  3  days;  T3:  RA  and  BMP4  were  applied  for  all  5  days,  but  
TGF-β2  was  only  applied  the  first  2  days  ( Fig.  13 ).  In  the  regimen  of  T1,  the  expression  of  
MYOC,  MGP,  FOXC1,  and  PAWR  were  significantly  increased  with  the  treatment  of  5  days,  
the  expression  of  PITX2  and  FOXC2  were  also  increased  after  2  days  treatment  but  not  5  
days  treatment.  In  the  regimen  of  T2,  only  the  expression  of  PITX2  was  increased  after  2  days  
treatment  but  not  5  days  treatment.  In  the  regimen  of  T3,  the  expression  of  PITX2  was  also  
increased  after  2  days  treatment  but  not  5  days  treatment,  and  the  expression  of  PAWR  was  
significantly  increased  for  both  2  days  treatment  and  5  days  treatment.  Thus,  the  regimen  of  
T1  is  the  most  promising  method  of  the  differentiation  from  DP-MSCs  to  TM-like  cells.  With  
the  treatment  of  all  three  growth  factors  for  5  days,  TMC  markers  were  assessed  and  
functional  assays  were  performed.  
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Figure  13:  Different  combinations  of  RA,  TGF-β2,  and  BMP4  alter  the  expression  of  TMC  
markers  in  DP-MSCs.  A)-F):  Relative  expressions  of  MYOC,  MGP,  PITX2,  FOXC1,  FOXC2,  
and  PAWR  were  normalized  to  EEF2,  T1,  T2,  and  T3  are  different  treatment  regimens.  T1:  all  
growth  factors  were  applied  for  five  days;  T2:  TGF-β2  were  applied  for  the  first  2  days,  then  
RA  and  BMP4  were  applied  for  the  last  3  days;  T3:  RA  and  BMP4  were  applied  for  all  5  
days,  but  TGF-β2  was  only  applied  the  first  2  days  (adapted  from  McDonald,   2015  135 ).  
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5.2  TM  gene  markers  in  DP-MSCs  in  response  to  RA,  TGF-β2  and  BMP4  
This  growth  factors  treatment  experiment  was  performed  three  times  for  each  group  (N=3),  
and  the  expression  of  TMC  gene  markers  was  determined  by  qRT-PCR.  The  expression  of  
AQP1,  CHI3L1,MGP  and  MMP3  showed  no  statistical  difference  between  human  TMCs  and  
DP-MSCs  with/without  growth  factors.  The  expression  of  TIMP2  and  FOXC2  showed  no  
difference  between  DP-MSCs  with/without  growth  factors,  but  had  lower  expression  in  
TMCs.  The  expression  of  PAWR  was  higher  in  DP-MSCs  than  TMCs,  and  increased  further 
following  treatment  with  growth  factors.  LMX1B  was  expressed  in  TMCs,  but  was  not  
detectable  in  DP-MSCs  with/without  growth  factors.  The  expression  of  PITX2  was  detected  
in  TMCs,  but  was  substantially  lower  in  growth  factor  treated  DP-MSCs,  and  was  not  
detected  in  DP-MCSs  without  growth  factors  ( Fig.  14 ).  
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Figure  14:  Trabecular  meshwork  cell  markers  in  trabecular  meshwork  cells  and  dental  pulp  
mesenchymal  stem  cells  with  or  without  the  treatment  of  growth  factors.  A)-J):   Relative  
expression  of  AQP1,  CHI3L1,  LMX1B,  MGP,  MMP3,  TIMP2,  PITX2,  FOXC1,  FOXC2,  and  
PAWR  were  normalized  to  EEF2.   
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5.3  Expression  of  MYOC  in  response  to  dexamethasone  in  DP-MSC  after  the  
treatment  with  the  combination  of  RA,  TGF-β2,  and  BMP4.  
As  human  primary  TMCs  showed  a  characteristic  of  upregulated  expression  of  MYOC  in  
response  to  dexamethasone,  we  applied  this  assay  to  DP-MSCs  that  had  been   treated  with  
growth  factors.  In  this  experiment,  after  applying  the  established  growth  factor  treatment,   1  
μM  dexamethasone  or  0.1%  ethanol  is  added  for  the  last  three  days.  The  relative  expression  
level  of  MYOC  mRNA  in  the  growth  factors  groups  (GF+,  DEX-  and  GF+,  DEX+)  was  
significantly  higher  (9  fold)  compared  to  the  concentration  in  groups  not  exposed  to  these  
growth  factors  (GF-,  DEX-  and  GF-,  DEX+)  (P  <  0.001).  However,  levels  of  MYOC  mRNA  
did  not  show  significant  changes  associated  with  dexamethasone  treatment  in  the  growth  
factor  treated  cells  or  the  non-treated  cells  ( Fig.  15 A).  The  concentration  of  secreted  myocilin  
was  determined  by  ELISA  and  it  showed  a  similar  result.  The  concentration  of  MYOC  protein  
in  growth  factors  groups  was  significantly  higher  compared  to  the  concentration  in  cells  
which  were  not  exposed  to  the  growth  factors  for  both  dexamethasone  treated  cells,  which  
increased  from  1.266±0.116  ng/ml  to  2.657±0.235  ng/ml  (p-value  <0.001)  and  
non-dexamethasone-treated  groups,  which  increased  from  1.332±0.071  ng/ml  to  3.21±0.18  
ng/ml  (p-value  <0.001).  However,  the  secretion  of  myocilin  in  cells  was  not  significantly  
affected  by  treatment  with  dexamethasone.  ( Fig.  15 B).  
  
Figure  15:  Dexamethasone  induced  myocilin  secretion  assay  in  DP-MSCs  after  the  treatment  
of  the  combination  of  growth  factors  of  RA,  TGF-β2,  and  BMP4.  A)  Relative  expression  of  
MYOC  with/without  the  treatment  of  dexamethasone  normalized  to  EEF2;  B)  Secreted  





5.4  Contractile  ability  in  TMCs  and  DP-MSCs   
Primary  human  TMCs  and  growth  factor  treated  DP-MSCs  were  tested  for  their  ability  to  
contract  to  the  extracellular  matrix.  TMCs  and  fibroblast  showed  a  great  contractility  to  the  
collagen  gel  and  this  ability  can  be  inhibited  by  Y-27632.  The  collagen  gel  area  was  
decreased  by  1.005±0.019  cm 2   and  1.007±0.074  cm 2   in  the  groups  of  TMCs  and  fibroblast,  
respectively,  within  24  hours.  While  10  μM  Y-27632  was  included,  the  change  of  the  collagen  
gel  area  was  shrunk  to  0.231±0.219  cm 2   and  0.604±0.098  cm 2 ,  respectively.  However,  there  
was  no  detectable  contraction  of  the  collagen  gel  area  in  the  DP-MSCs  with  or  without  the  
treatment  with  the  growth  factors  over  the  whole  experimental  time  period  of  72  hours  ( Fig.  
16 ).  
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Figure  16:  Collagen  gel  contraction  assay.  A)  Representative  photographs  of  collagen  gel  
cultures  of  DP-MSCs  with/without  growth  factors,  TMCs  with/without  10μM  Y-27632  and  
fibroblast  with/without  10  μM  Y-27632;  B)  The  decrease  in  area  of  the  collagen  gel  during  




6.  RESULTS:  Structural  and  functional  profiling  in  trabecular  meshwork  
cells  of  genes  putatively  involved  with  variation  in  intraocular  pressure.  
  
6.1  Cell  painting  Assay  for  Crop-seq  experiment  in  trabecular  meshwork  cells  
In  this  assay,  we  aimed  to  create  image  profiles  for  each  of  the  gene  knockout  and  identify  
any  distinct  morphological  groups.  A  total  210,243  individual  cells  were  identified  by  the  
software  of  CellProfiler,  together  with  1053  morphological  features  (Appendix.  List  1).  
   
6.1.1  Feature  transformation  and  normalization  
The  shape  of  the  distribution  varies  across  the  features  ( Fig.  17 ).  It  is  important  to  transform  
the  feature  values  when  approximately  normally  distributed  data  have  centered  mean  value  
and  comparable  standard  deviation  value.  Proper  distribution  of  features  enables  us  to  extend  
the  data  from  individual  cells  to  the  whole  well.  The  algorithms  of  the  generalized  logarithm  
and  Box-Cox  transformation  were  applied  to  our  non-targeting  control  groups.  
Anderson-Darling  test  was  performed  to  compute  ratios  of  deviation  from  normality.  The  
lower  the  value  of  Anderson-Darling  test,  the  more  similar  the  distribution  is  to  the  normal  
distribution.  The  Box-Cox  transformation  shows  a  better  effect  compared  to  the  generalized  
logarithm  on  the  normality  transformation  ( Fig.  18 )  and  hence  was  used  for  next  analysis.  
The  procedure  of  normalization  was  introduced  in  the  Method  section  3.5.5.1.  
  




Figure  17:  Diversity  of  feature  distributions  in  morphological  profiling.  A)-F)  Morphological  
features  exhibit  various  types  of  distributions,  including  A)  normal,  B),C),E)  skewed,  D)  
uniform,  F)  discrete  distribution.  These  histograms  were  obtained  with  feature  value  from  our  
human  non-targeting  control  cells  (45,446  cells).  The  x  axes  show  the  feature  values,  and  the 
y  axes  show  frequencies  (cell  counts).   
  
  




Figure  18:  Anderson−Darling  normality  test  in  the  morphological  profiles  of  control  groups.   
The  y  axes  show  the  statistic  A  value,  the  lower  the  value  is,  the  closer  to  normality  
distribution  of  the  feature,  and  the  x  axes  are  the  features  re  ordered  by  the  mean  statistic  A  
value  of  the  three  groups:  raw  data(Blue),  generalized  logarithm  transformation(Green),  and  
Box-Cox  transformation(Red).  
  
  
6.1.2  Investigation  of  well-well  variation:  
In  the  cell  painting  experiment,  we  set  up  three  wells  for  each  gene  knockout  group  with  
triplicates  in  each  plate,  so  each  gene  knockout  group  has  nine  wells  total.  To  minimize  the  
plate  layout  effect,  we  only  used  the  inner  wells  of  a  96-well  plate,  all  groups  including  
controls  were  randomly  located  across  fifteen  96-well  plates,  and  located  in  edge  wells.  In  the  
gene  knockout  groups  of  ANAPC1  and  LTBP2 ,  one  batch  of  cells  was  lost  during  the  
puromycin  selection,  so  only  six  wells  of  cells  were  seeded  for  these  two  groups.  For  the  
human  non-targeting  control  group,  we  set  up  five  different  pairs  of  human  non-targeting  
gene  control  groups  which  were  seeded  with  triplicates  in  each  plate,  so  our  control  group  has  
225  wells.  In  total,  777  wells  were  seeded  and  captured  for  62  gene  knockout  groups  and  
human  non  targeting  groups.   
Well  profiles  were  created  by  aggregating  the  value  of  individual  cells  to  the  median  value.  
For  each  of  our  gene  knockout  groups  and  human  non  targeting  controls,  the  Spearman’s  rank  
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correlation  coefficient  was  calculated  between  each  pair  of  replicates.  We  initially  checked  
how  batch  effects,  which  are  subgroups  of  measurements  that  result  from  undesired  technical  
variation  such  as  instrument  calibration,  sample  manipulation  and  changes  in  laboratory  
conditions,  may  be  affecting  our  data.  The  batch  effect  varies  across  different  groups  ( Fig.  19 ,  
).  The  groups  such  as  BCAS3,  LMX1B,  ME3  showed  a  strong  batch  effect  and  low  correlation  
coefficient  ( Fig.  20 _14,  39,  41)  but  other  groups  such  as  CAPZA1,  CAV2,  ETS1  showed  less  
batch  effect  ( Fig.  20 _15,  16,  26),  also,  our  human  non  targeting  controls  also  showed  a  low  
correlationship  when  involving  all  the  control  wells  ( Fig.  19 ,  Fig.  20 _63).   To  minimize  the  
batch  effects,  we  only  selected  the  wells  with  a  Spearman’s  rank  correlation  coefficient  >  0.2,  
which  was  397  wells  out  of  777  ( Fig.  21 ).  This  procedure  enables  us  to  aggregate  the  data  of  
each  feature  from  individual  cells  to  their  corresponding  groups.  
  
Figure  19:  Spearman's  rank  correlation  coefficient  in  each  of  the  gene  knockout  group  and  
human  non  targeting  group.  The  x  axes  are  the  gene  knockout  groups  and  human  
non-targeting  control  groups.  The  y  axes  show  the  Spearman’s  rank  correlation  coefficient  








Figure  20:  Spearman's  rank  correlation  coefficient  matrix  in  each  gene  knockout  group  and  
human  non  targeting  control  group.  The  matrix  shows  the  Spearman’s  value  between  each  
pair  of  replicates.  The  title  of  each  matrix  is  the  gene  which  is  knockout  in  that  group,  the  
groups  of  ANAPC1  and  LTBP2  have  6  wells  and  rest  groups  have  9  wells.  The  matrix  of  









Figure  21:  Filter  wells  with  Spearman's  rank  correlation  coefficient  >  0.2  for  each  gene  
knockout  group  and  human  non  targeting  control  group.  
  
  
6.1.3  Feature  selection  
To  reduce  the  redundancy  of  the  features,  the  method  of  correlation_threshold  was  applied  to  
the  individual  cell  data.  This  method  iteratively  removed  highly  correlated  features  ( i.e.  those  
with  a  pearson  value  >0.9  compared  the  rest  of  the  features).  Finally,  the  profiles  of  each  gene  
knockout  group  and  human  non-targeting  control  were  created  by  aggregating  the  individual  
cell  data  to  the  median  value  and  a  data  frame  was  generated  with  a  dimension  of  63  groups  
across  425  features  ( Fig.  22 ).  
  
  




Figure  22:  Heatmap  displaying  the  median  value  of  each  feature  for  each  gene  knockout  
group  and  human  non  targeting  control  group.  The  x  axes  are  the  groups,  and  the  y  axes  are  




6.1.4  Morphological  features-enriched  hierarchical  clustering  
To  determine  how  the  morphological  profiles  of  the  knockout  genes  might  be  related  to  one  
another,  we  performed  clustering  analysis.  The  euclidean  distance  was  computed  between  
each  pair  of  the  groups  ( Fig.  23 ),  and  the  hierarchical  clustering  method  of  ward.D2  was  
applied  to  generate  the  cutree,  where  the  distance  between  each  group  within  one  branch  is  
closer  than  those  located  in  different  branches  ( Fig.  24 ).  The  gene  knockout  groups  of  
PLEKHA7,  GMDS,  PTPRJ  were  clustered  together  with  a  morphological  pattern  of  high  
granularity  value  features  in  the  AGP  channel,  in  which  the  phalloidin  and  WGA  were  used  
to  stain  the  actin,  golgi  apparatus,  and  plasma  membrane  ( Fig.  22 ,  Fig.  25  A).   
  
In  the  comparison  between  the  genes  at  the  overlapping  loci,  CAV1,  CAV2 ,  and  TES   at  
chromosome  7  showed  a  similar  morphological  pattern,  as  well  as  EMID1  and  KREMEN1 ,  
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GNB1L  and  TXNRD2  at  chromosome  22  ( Fig.  22 ,  Fig.  25  A).  At  chromosome  1,  the  TMCO1  
showed  a  more  similar  pattern  to  the  non-targeting  control  groups  than  the  gene  knockout  
group  of  ALDH9A1 ,  and  the  ALDH9A1  group  showed  a  low  granularity  in  the  AGP  channel  
and  mitochondrial  channel  ( Fig.  22 ,  Fig.  25  A).  At  chromosome  9,  the  gene  knockout  group  
showed  a  pattern  with  lower  granularity  than  the  groups  of  RALGPS1  and  LMX1B  ( Fig.  22 ,  
Fig.  25  A).  At  chromosome  11,  ME3  showed  a  low  granularity  pattern  in  the  AGP  and  
mitochondrial  channel  while  the  group  of  PRSS23  was  more  similar  to  the  non  targeting  
controls  ( Fig.  25  A,  B).  
  
In  the  groups  of  genes  related  to  the  congenital  glaucoma,  GMDS,  CYP1B1,  TEK,  FOXC1,  
and  LTBP2 ,  the  GMDS  knockout  groups  showed  a  high  granularity  pattern  while  the  FOXC1  
groups  showed  a  low  granularity  pattern  ( Fig.  22 ,  Fig.  25  A,  B).   




Figure  23:  Euclidean  distance  matrix  between  each  of  the  gene  knockout  groups  and  human  
non  targeting  group  of  the  morphological  features.  Groups  are  ordered  by  the  hierarchical  
clustering  methods  of  ward.D2.  The  bottom  grid  shows  the  genes  within  or  nearby  the  same  
loci  at  the  chromosome  and  the  potential  positive  genes  (blue)  associated  with  congenital  
glaucoma,  human  non  targeting  control  group  is  marked  in  red.   
  
  




Figure  24:  Cluster  tree  displaying  the  hierarchical  clustering  of  each  cell  line  based  on  the  
morphological  profiles.  The  method  of  ward.D2  was  applied,  the  distance  between  each  
group  within  one  branch  was  closer  than  those  located  in  different  branches.  The  bottom  grid  
shows  the  genes  within  or  nearby  the  same  loci  at  the  chromosome  and  the  potential  positive  
genes  (blue)  associated  with  congenital  glaucoma,  human  non  targeting  control  group  is  







Figure  25:  The  median  value  of  selected  features,  Cytoplasm_Granularity_15_corAGP(A)  
and  Nuclei_Granularity_9_corMito(B)  in  each  gene  knockout  group  and  human-non  
targeting  control  group.  The  x  axis  shows  each  group,  the  bottom  grid  shows  the  genes  within  
or  nearby  the  same  loci  at  the  chromosome  and  the  potential  positive  genes  (blue)  associated  
with  congenital  glaucoma,  human  non  targeting  control  group  is  marked  in  red.  The  y  axis  is  







6.2  Single  cell  transcriptional  profiling  of  trabecular  meshwork  cells  
In  this  assay,  the  sgRNAs  of  each  knockout  gene  were  assigned  to  individual  cells  when  the  
sgRNA  was  the  only  designed  sgRNA  found  in  the  cell  or  the  reads  of  the  sgRNA  were  more  
than  three  times  of  the  sum  of  other  sgRNAs  which  targeting  other  genes.  The  data  of  single  
cell  transcriptome  was  normalised  using  SCTransform  and  stored  in  a  Seurat  object  via  R.  
( https://github.com/powellgenomicslab/CROP-seq ).  Total  25,879  high  quality  single  cell  
transcriptomes  were  obtained  ( Fig.  26 ).  
  
Figure  26:  UMAP  plots  of  the  scRNA-seq.  25,879  cells  are  plotted  and  coloured  by  their  









6.2.1  Differential  expression  analysis  
To  study  the  effects  of  each  sgRNA  on  the  transcriptome,  we  compared  the  gene  expression  
level  of  each  62  gene  knockout  groups  to  the  human  non-targeting  control  group  ( Fig.  27 ,  
Appendix  Figure  1).  The  differentially  expressed  genes  (DEGs)  were  selected  with  the  rules  
of  log2_fold_change  >  2  and  p  value  <  10 -6   (Appendix.  Table  3).  Among  these  62  
comparisons,  total  240  DEGs  were  selected.  Then  we  generated  a  data  frame  of  the  
log2_fold_change  value  of  DEGs  for  all  62  gene  knockout  groups  together  with  the  human  
non-targeting  controls.  The  log2_fold_change  value  was  set  to  0  for  the  human  non  targeting  
controls  ( Fig.  28 ).   
  
Figure  27:  Differential  expressed  genes  between  gene  knockout  groups  compared  to  
non-targeting  control  groups.  1)  ABCA1,  2)  ABO,  3)  ADAMTS6,  4)  AFAP1,  5)  ALDH9A1,  6)  
ANAPC1,  7)  ANGPT1,  8)  ANGPT2,  9)  ANGPTL2,  10)  ANKH,  11)  ANTXR1,  12)  ARHGEF12,  
13)  ATXN2,  14)  BCAS3,  15)  CAPZA1,  16)  CAV1,  17)  CAV2,  18)  CDH11,  19)  COL24A1,  20)  
CTTNBP2,  21)  CYP1B1,  22)  DGKG,  23)  EFEMP1,  24)  EMCN,  25)  EMID1,  26)  ETS1,  27)  
FBXO32,  28)  FER,  29)  FERMT2,  30)  FMNL2,  31)  FNDC3B,  32)  FOXC1,  33)  GAS7,  34)  
GMDS,  35)  GNB1L,  36)  KALRN,  37)  KREMEN1,  38)  LMO7,  39)  LMX1B,  40)  LTBP2,  41)  
ME3,  42)  MECOM,  43)  MYOC,  44)  MYOF,  45)  PARD3B,  46)  PDE7B,  47)  PKHD1,  48)  
PLEKHA7,  49)  PRSS23,  50)  PTPRJ,  51)  RALGPS1,  52)  RUNX2,  53)  SPTBN1,  54)  TEK,  55)  
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Figure  28:  Heatmap  displaying  the  log2  fold  change  of  each  differentially  expressed  gene  




6.2.2  Hierarchical  clustering  of  enriched  differentially  expressed  genes   
In  clustering  analysis,  the  euclidean  distance  was  computed  between  each  pair  of  the  groups  
with  the  expression  level  of  DEGs  ( Fig.  29 ),  the  hierarchical  clustering  method  of  ward.D2  
was  applied  to  generate  the  cutree  ( Fig.  30 ).  The  gene  knockout  groups  of  ABCA1,  
ADAMTS6,  ANAPC1,  ANGPT1,  ANGPTL2,  ATXN2,  FBXO32,  FER,  FERMT2,  FMNL2,  
FNDC3B,  GAS7,  MECOM,  PARD3B,  PDE7B,  PRSS23,  TIMP3,  TMCO1,  and  ZNF280D  are  
clustered  together  and  were  more  distant  to  other  groups  including  the  control  ( Fig.  28 ,  Fig.  
29 ,  Fig.  30 ).  In  this  cluster,  the  top  20  upregulated  DEGs  are  TAC1,  IL1RN,  MMP10,  
HS3ST2,  OASL,  IFIT2,  CHODL,  RSAD2,  IFI44L,  MX1,  ISG15,  IFIT1,  OAS1,  MX2,  CMPK2,  
IFI6,  OAS2,  OAS3,  XAF1,  and   IFIT3 ,  and  the  tail  20  downregulated  DEGs  are  APCDD1,  
PRELP,  ANKRD33B,  PLAAT4,  LYPD6B,  ALDH1A1,  CPA4,  PGF,  KIT,  LCE2A,  EXPH5,  
MEST,  GPRC5A,  USP53,  CCL2,  VSIR,  GASK1B,  HES1,  MGARP,  EFEMP1  ( Fig.  28 ).  The  
gene  ontology  analysis  on  these  DEGs  were  performed  using  the  online  tool  metascape  
( https://metascape.org/ ) 136   and  13  upregulated  DEGs  are  found  related  to  the  interferon  
alpha/beta  signaling  including  IL1RN,  OASL,  IFIT2,  RSAD2,  MX1,  IFIT1,  OAS1,  MX2,  IFI6,  
OAS2,  OAS3,  XAF1,  IFIT3  ( Fig.  31 ).   
  
In  the  comparison  between  the  genes  at  the  overlapping  loci,  the  gene  knockout  groups  of  
TMCO1  (at  chromosome  1)  and  PRSS23  (at  chromosome  11)  present  distinct  DEG  patterns  to  
the  control  groups  ( Fig.  27 _58,  41).  Other  groups  show  a  similar  DEGs  patterns  to  the  control  
groups,  including  ALDH9A1  (at  chromosome  1)  ( Fig.  27 _5),   CAV1,  CAV2 ,  and  TES  (At  
chromosome  7)  ( Fig.  27 _16,  17,  55),  ANGPT2,  RALGPS1,  and  LMX1B  (at  chromosome  9)  
( Fig.  27 _8,  51,  39),  ME3  (at  chromosome  11)  ( Fig.  27 _43),  EMID1  and  KREMEN1  (at  
chromosome  22  q11)  ( Fig.  27 _25,  37)  ,  GNB1L  and  TXNRD2  (chromosome  22  q12)  ( Fig. 
27 _35,  61).   
  
All  the  gene  knockout  groups  related  to  the  congenital  glaucoma  showed  similar  patterns  to  
controls,  including  GMDS  ( Fig.  27 _34),  CYP1B1  ( Fig.  27 _21),  TEK  ( Fig.  27 _54),  FOXC1  
( Fig.  27 _32),  and  LTBP2  ( Fig.  27 _40).   
  




Figure  29:  Euclidean  distance  matrix  between  each  of  the  gene  knockout  groups  and  human  
non  targeting  group  of  the  differential  expressed  genes.  Groups  are  ordered  by  the  
hierarchical  clustering  methods  of  ward.D2.  The  bottom  grid  shows  the  genes  within  or  
nearby  the  same  loci  at  the  chromosome  and  the  potential  positive  genes  (blue)  associated  









Figure  30:  Cluster  tree  displaying  the  hierarchical  clustering  of  each  cell  line  based  on  the  
RNA  expression  profiles.  The  method  of  ward.D2  was  applied,  the  distance  between  each  
group  within  one  branch  was  closer  than  those  located  in  different  branches.  The  bottom  grid  
shows  the  genes  within  or  nearby  the  same  loci  at  the  chromosome  and  the  potential  positive  
genes  (blue)  associated  with  congenital  glaucoma,  human  non-targeting  control  group  is  





Figure  31:  Gene  ontology  enrichment  analysis  of  the  selected  DEGs.  Top  8  clusters  with  
their  representative  enriched  terms.  For  each  given  gene  list,  pathway  and  process  
enrichment  analysis  was  performed  with  the  ontology  sources:  KEGG  Pathway,  GO  
Biological  Processes,  Reactome  Gene  Sets,  Canonical  Pathways  and  CORUM.  All  genes  in  
the  genome  have  been  used  as  the  enrichment  background.  Terms  with  a  p-value  <  0.01,  a  
minimum  count  of  3,  and  an  enrichment  factor  >  1.5  (the  enrichment  factor  is  the  ratio  
between  the  observed  counts  and  the  counts  expected  by  chance)  are  collected  and  grouped  
into  clusters  based  on  their  membership  similarities.  Each  cluster  has  "Log10(P)"  is  the  
p-value  in  log  base  10.  
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7.  DISCUSSION   
POAG  is  a  heterogeneous  disease  influenced  by  complex  interactions  of  risk  factors  
including  the  age,  ethnicity,  family  history,  the  use  of  corticosteroids,  and  intraocular  
pressure.  Although  the  genetic  basis  of  POAG  is  complex,  many  genetic  risk  factors  have  
been  identified  and  their  roles  in  pathogenesis  of  POAG  have  become  more  clear  137 .  For  
example,  mutations  in  MYOC  cause  an  elevated  IOP  and  dysfunction  of  TMCs,  while  OPTN  
and  TBK1  mutations  are  more  closely  related  to  the  nervous  system  processes  in  glaucoma  
with  a  normal  IOP  14,15,138 .  To  investigate  cellular  changes  occurring  in  glaucoma,  there  is  a  
demand  to  find  more  relevant  models  to  study  the  gene  mutations.  TMCs  are  always  the  first  
choice  since  they  are  related  to  the  IOP  directly,  however,  the  difficulty  in  harvesting  the  cells  
from  TM  tissue  limits  the  usage  of  TMCs.  Since  TMCs  are  isolated  from  TM  tissue  and  
cultured  in  vitro,  they  should  be  treated  as  “secondary”  cultures  (passage  2),  and  they  have  a  
finite  number  of  doublings.  Their  appearance  begins  to  change  after  6  passages,  such  as  
vacuoles,  increased  size  and  reduced  doubling  time.  Thus,  the  human  primary  TMCs  can  only  
be  used  no  later  than  7  passages  77 .  Although  there  exists  a  commercial  cell  line  called  TMCs,  
they  are  of  doubtful  quality  since  they  did  not  show  a  TMC-like  response  to  the  treatment  
with  corticosteroids  90 .   
  
Our  first  aim  is  to  investigate  whether  the  combination  treatment  of  the  growth  factors,  RA,  
TGF-β2,  and  BMP4  could  induce  DP-MSCs  to  become  TM-like  cells.  The  results  show  that  
the  5  days  treatment  of  these  growth  factors  can  upregulate  the  expression  of  POM  markers  
of  PITX2 ,  FOXC1 ,  and  FOXC2 ,  as  well  as  the  PITX2  regulator  PAWR .  These  four  genes  
interact  with  each  other  and  are  involved  in  a  common  regulatory  network  for  the  
development  of  anterior  segment  of  the  eye.  FOXC1  and  FOXC2  have  similar  structure  and  
expression  patterns.  PITX2  can  inhibit  the  activity  of  FOXC1 ,  while  PAWR  can  inhibit  the  
activity  of  PITX2  alone,  but  together  with  FOXC1  or  FOXC2 ,  PAWR  increases  the  activity  of  
PITX2  139 .  Thus,  the  upregulation  of  these  genes  may  cause  DP-MSCs  to  develop  some  
features  of  TMCs.  Our  results  show  the  TMC  marker  MYOC  mRNA  and  secreted  MYOC 
protein  were  upregulated  in  DP-MSCs  with  the  growth  factors  treatment.   However,  for  some  
genes,  the  data  is  highly  variable,  which  may  in  part  due  to  many  genes  being  lowly  
expressed  with  Ct  values  close  to  threshold  for  DP-MSCs,  either  with  or  without  the  
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treatment  of  growth  factors.  This  variability  may  mean  that  the  experiments  were  
underpowered  for  quantifying  expression  of  some  genes  such  as  AQP1,  CHI3L1,  MGP,  and  
MMP3 ,  and  should  be  repeated  with  additional  replicates.  However,  the  mRNA  expression  
levels  of  several  other  genes  including  LMX1B,  TIMP2,  PITX2,  FOXC2,  and  PAWR  did  
reveal  statistically  significant  differences  between  human  TMCs  and  DP-MSCs  with  the  
growth  factors  treatment,  and  the  growth  factors  treated  DP-MSCs  did  not  present  the  
functional  properties  associated  with  TMCs  such  as  the  response  to  dexamethasone  and  the  
contractile  ability  to  collagen.  Therefore,  it  is  clear  that  exposure  to  RA,  TGF-β2  and  BMP4  
is  insufficient  to  differentiate  DP-MSCs  to  TM-like  cells.  
  
The  second  study  sought  to  investigate  the  effects  of  IOP-associated  gene  knockouts  on  the  
morphological  and  transcriptome  profiles  of  primary  human  TMCs.  It  is  the  first  time  we  
combined  the  techniques  of  CellPainting,  scRNA-seq  and  CRISPR  together  to  study  the  gene  
knockout  effects  in  vitro .   
  
In  the  gene  knockout  groups  with  genes  related  to  congenital  glaucoma,  GMDS,  FOXC1,  
LTBP2,  TEK,  and  CYP1B1 ,  we  expected  to  see  distinct  patterns  on  the  gene  expression  and  
morphology.  However,  no  distinct  patterns  were  observed  in  the  transcriptome  of  these  gene  
knockout  groups.  In  contrast,  the  GMDS  knockout  group  exhibits  a  pattern  with  high  value  of  
granularity  in  AGP  channel  and  the  FOXC1  knockout  group  exhibits  a  pattern  with  a  low  
value  of  granularity  features  in  both  AGP  channel  and  mitochondrial  channel.  The  features  in  
AGP  channels  are  related  to  the  status  of  actin,  golgi  apparatus  and  plasma  membrane  and  the  
features  in  mitochondrial  channel  refer  to  the  activity  of  mitochondria.  Previous  study  of  
FOXC1  knock  down  with  small  interfering  RNA  demonstrates  that  FOXC1  can  affect  the  
expression  849  genes,  357  of  which  were  enriched  to  the  gene  ontology  term  membrane  140 .  
Thus,  the  morphological  profiles  of  FOXC1  knockout  group  may  reflect  changed  gene  
regulation  in  TMCs.   
  
In  the  gene  knockout  groups  with  genes  at  overlapping  loci,  TMCO1  and  ALDH9A1  at  
chromosome  1  q24,  CAV1,  CAV2  and  TES  at  chromosome  7  q21,  ANGPTL2,  RALGPS1,  and  
LMX1B  at  chromosome  9  q33,  ME3  and  PRSS23  at  chromosome  11  q14,  TXNRD2  and  
GNB1L  at  chromosome  22  q11,  and  KREMEN1  and  EMID1  at  chromosome  22q12,  we  aimed  
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to  see  distinct  patterns  of  gene  expression  and  morphology  in  each  pair  of  genes  when  
compared  to  the  control  group,  so  we  could  identify  the  true  hit  for  that  loci.  In  the  
transcriptome  profiles,  the  gene  knockout  groups  of  TMCO1  and  PRSS23  exhibit  a  pattern  
distinct  to  control  groups,  which  contains  a  group  of  upregulated  DEGs  related  to  the  
interferon  alpha/beta  signaling.  The  rest  of  the  gene  knockout  groups  seem  to  be  similar  to  
the  controls.  Interestingly,  MYOC  was  upregulated  significantly  in  the  gene  knockout  group  
of  CAV2 ,  which  suggests  CAV2  is  involved  in  the  regulation  of  myocilin.   
The  morphological  profiles  present  a  different  scenario  to  the  cell  transcriptomes  in  some  
cases.  The  gene  knockout  group  of  ALDH9A1  and  ME3  show  distinct  patterns  with  a  low  e  
granularity  of  features  in  the  mitochondrial  channel  compared  to  the  controls.  ALDH9A1  
encodes  aldehyde  dehydrogenases,  which  has  a  high  level  of  oxidation  activity  141 .  ME3  
encodes  an  NADP-dependent  malic  enzyme  involved  in  carbohydrate  metabolism,  and  it  was  
found  to  be  associated  with  POAG  in  a  study  of  mitochondrial  genetic  variation  142 .  Thus,  
ALDH9A1  and  ME3  should  be  positive  hits  associated  with  POAG.   
  
The  differences  between  the  transcriptome  and  morphological  profiles  could  be  due  to  the  
different  calculation  method  for  each  profile.  In  transcriptome  profiles,  DEGs  were  selected  
by  comparing  each  gene  knockout  group  versus  the  control  group  following  the  criteria  of  
fold  change  >  4  and  the  p  value  <  10 -6 ,  then  the  relative  expression  level  compared  to  the  
controls  was  selected  to  represent  each  gene  knockout  group.  However,  the  relative  
expression  level  reflects  the  mean  expression  level  of  all  the  cells  in  that  group,  which  could  
be  affected  by  the  distribution  of  the  dataset  and  the  outliers.  A  recent  scRNA-seq  study  
identified  19  cell  types  in  the  human  primary  TMCs  which  suggests  the  dataset  could  follow  
a  multimodal  distribution  across  different  cell  types  143 ,  hence  our  group  mean  expression  
levels  may  not  be  truly  representative  of  the  data.   In  contrast,  we  generated  the  
morphological  profiles  using  the  median  value  of  each  feature,  which  is  more  robust  when  
the  dataset  was  not  normally  distributed  or  contained  outliers  131 .  Consequently,  our  
morphological  profiles  should  be  more  representative.  
  
In  summary,  this  work  is  the  first  time  that  high-throughput  morphological  profiling  
(CellPainting)  has  been  combined  with  scRNA-seq  analysis.  Together,  these  platforms  have  
uncovered  unifying  pathways  involved  in  the  homeostasis  of  TMCs,  variation  in  IOP,  and  the  
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pathogenesis  of  glaucoma.  Robust  pipelines  have  been  generated  to  create  the  profiles  of  
transcriptome  and  cell  morphology.  These  results  demonstrate  the  gene  perturbation  can  be  
reflected  in  the  cell  morphology  with  corresponding  regulatory  pathway,  and  as  a  
consequence  this  resource  further  improves  our  understanding  of  gene  function  in  disease.   




8.  CONCLUSIONS  AND  FUTURE  DIRECTIONS  
There  are  two  main  overarching  conclusions  from  this  body  of  research.  Firstly,  although  
DP-MSCs  express  markers  of  TMCs  following  the  exposure  of  a  combination  of  
transcription  factors,  they  have  not  acquired  characteristic  functional  properties  of  TMCs.  
Secondly,  high  throughput  analysis  of  cellular  structure  and  function  through  cellpainting  and  
scRNA-seq  assays  enabled  the  direct  study  of  genetic  perturbations  at  the  single  cell  
resolution.  Overall,  this  work  provides  a  framework  for  investigating  the  role  of  genes  
involved  in  the  pathogenesis  of  glaucoma  in  both  genetic  and  morphology.  
  
Previous  methods  of  generating  TM-like  cells  have  been  successful  by  directly  co-culturing  
induced  pluripotent  cells  with  primary  human  TMCs.  As  such  it  is  clear  that  other  factors  
secreted  from  TMCs  may  contribute  to  the  differentiation  to  TM-like  cells.  These  growth  
factors  may  include  epidermal  growth  factor  (EGF),  hepatocyte  growth  factor  (HGF),  insulin  
like  growth  factor  (IGF)-1,  tumor  necrosis  factor  (TNF)  a,  platelet-derived  growth  factor  
(PDGF)-AA,  PDGF-BB,  PDGF-AB,  and  basic  fibroblast  growth  factor  (FGF-2)  144 .  As  such,  
further  work  investigating  additional  growth  factors  which  may  be  crucial  in  the  maintenance  
of  primary  TMCs  cultures  and  prolong  the  doubling  time  in  vitro ,  should  be  undertaken.  To  
follow-up  previous  research  135 ,  we  examined  the  expression  level  of  the  common  markers,  
MYOC,  MGP,  CHI3L1 ,  which  were  also  implicated  in  the  work  of  Sathiyanathan  and  
colleagues  145 .  In  ongoing  differentiation  experiments  of  TMCs,  additional  specific  markers  
for  TMCs  should  be  involved,  which  include  CDH23,  SPP1,  F5,  KCNAB1,  FGF9,  HEY1,  
and  BDNF,  as  distinctions  from  TM-MSCs,  cornea  and  sclera.   
  
In  regard  to  the  CROP-seq  experiments,  this  comprehensive  transcriptomic  and  the  
morphological  dataset  of  TMW  cells  represents  the  largest  functional  follow-up  of  genes  
implicated  through  GWAS  to  date.  In  the  gene  expression  comparison,  different  cell  types  
may  be  grouped  according  to  their  transcriptome  patterns  143   and  the  influence  of  the  
non-normal  distributions  and  outliers  may  be  minimized.  For  the  cell  morphology,  using  the  
median  value  of  each  feature,  and  adding  features’  dispersion  and  covariances  to  the  profiles  
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Appendix  Table.  1  Non-standard  abbreviations  
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Abbreviation  Full  name  
BMP4  bone  morphogenetic  protein  4  
BSA  Bovine  Serum  Albumin  
CRISPR  clustered  regularly  interspaced  short  palindromic  repeats  
CROP-seq  CRISPR  droplet  sequencing  
DEGs  differentially  expressed  genes  
DP-MSCs  dental  pulp-Mesenchymal  stem  cells  
ECM  extracellular  matrix  
ELISA  Enzyme-linked  immunosorbent  assay  
ER  endoplasmic  reticulum  
FACS  fluorescence  activated  cell  sorting  
FBS  fetal  bovine  serum  
GWAS  genome-wide  association  studies  
HDR  homology-directed  repair   
HNDF  human  neonatal  dermal  fibroblast  
IOP  Intraocular  pressure  
JCT  juxtacanalicular  tissue  
MSCs  mesenchymal  stem  cells  
NGS  next  generation  sequencing  
NHEJ  non-homologous  end  joining  
NTG  normal-tension  glaucoma  
PBA  sodium  4-phenylbutyrate  
PBS  phosphate-buffered  saline  
POAG  Primary  open-angle  glaucoma  
POM  periocular  mesenchyme  
RA  retinoic  acid  
RAR  retinoic  acid  receptor  
RGCs  retinal  ganglion  cells  
RNAi  RNA  interference  
ROCK  Rho  kinase  
ROS  reactive  oxygen  species  
RXR  retinoid  X  receptor  
scRNA-seq  single-cell  RNA  sequencing  
sgRNAs  single-guide  RNAs  
SNPs  single  nucleotide  polymorphisms  
SpCas9  Streptococcus  pyogenes  Cas9  
TGF-β2  transforming  growth  factor-β2  
TM  trabecular  meshwork  
TMCs  trabecular  meshwork  cells  
TNF-α  tumor  necrosis  factor  α  
UMI  unique  molecular  identifier  
WGA  Wheat  Germ  Agglutinin  
  
Appendix  Table.  2  Gene  name  abbreviations  for  genes  selected  for  CRISPR/Cas  
knockout  
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Abbreviation  Full  name  
ABCA1  ATP  binding  cassette  subfamily  A  member  1  
ABO  ABO,  alpha  1-3-N-acetylgalactosaminyltransferase  and  alpha  1-3-galactosyltransferase  
ADAMTS6  ADAM  metallopeptidase  with  thrombospondin  type  1  motif  6  
AFAP1  actin  filament  associated  protein  1  
ALDH9A1  aldehyde  dehydrogenase  9  family  member  A1  
ANAPC1  anaphase  promoting  complex  subunit  1  
ANGPT1  angiopoietin  1  
ANGPT2  angiopoietin  2  
ANGPTL2  angiopoietin  like  2  
ANKH  ANKH  inorganic  pyrophosphate  transport  regulator  
ANTXR1  ANTXR  cell  adhesion  molecule  1  
ARHGEF12  Rho  guanine  nucleotide  exchange  factor  12  
ATXN2  ataxin  2  
BCAS3  BCAS3  microtubule  associated  cell  migration  factor  
CAPZA1  capping  actin  protein  of  muscle  Z-line  subunit  alpha  1  
CAV1  caveolin  1  
CAV2  caveolin  2  
CDH11  cadherin  11  
COL24A1  collagen  type  XXIV  alpha  1  chain  
CTTNBP2  cortactin  binding  protein  2  
CYP1B1  cytochrome  P450  family  1  subfamily  B  member  1  
DGKG  diacylglycerol  kinase  gamma  
EFEMP1  EGF  containing  fibulin  extracellular  matrix  protein  1 
EMCN  endomucin  
EMID1  EMI  domain  containing  1  
ETS1  ETS  proto-oncogene  1,  transcription  factor  
FBXO32  F-box  protein  32  
FER  FER  tyrosine  kinase  
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FERMT2  fermitin  family  member  2  
FMNL2  formin  like  2  
FNDC3B  fibronectin  type  III  domain  containing  3B  
FOXC1  forkhead  box  C1  
GAS7  growth  arrest  specific  7  
GMDS  GDP-mannose  4,6-dehydratase  
GNB1L  G  protein  subunit  beta  1  like  
KALRN  kalirin  RhoGEF  kinase  
KREMEN1  kringle  containing  transmembrane  protein  1  
LMO7  LIM  domain  7  
LMX1B  LIM  homeobox  transcription  factor  1  beta  
LTBP2  latent  transforming  growth  factor  beta  binding  protein  2  
ME3  malic  enzyme  3  
MECOM  MDS1  and  EVI1  complex  locus  
MYOC  myocilin  
MYOF  myoferlin  
PARD3B  par-3  family  cell  polarity  regulator  beta  
PDE7B  phosphodiesterase  7B  
PKHD1  PKHD1  ciliary  IPT  domain  containing  fibrocystin/polyductin  
PLEKHA7  pleckstrin  homology  domain  containing  A7  
PRSS23  serine  protease  23  
PTPRJ  protein  tyrosine  phosphatase  receptor  type  J  
RALGPS1  Ral  GEF  with  PH  domain  and  SH3  binding  motif  1  
RUNX2  RUNX  family  transcription  factor  2  
SPTBN1  spectrin  beta,  non-erythrocytic  1  
TEK  TEK  receptor  tyrosine  kinase  
TES  testin  LIM  domain  protein  
TEX41  testis  expressed  41  
TIMP3  TIMP  metallopeptidase  inhibitor  3  
TMCO1  transmembrane  and  coiled-coil  domains  1  
TNS1  tensin  1  
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TXNRD2  thioredoxin  reductase  2  
ZNF280D  zinc  finger  protein  280D  
  
Appendix  Table.  3  Gene  name  abbreviations  identified  through  CROP-seq  
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Abbreviation  Full  name  
TAC1  tachykinin  precursor  1  
IL1RN  interleukin  1  receptor  antagonist  
MMP10  matrix  metallopeptidase  10  
OASL  2'-5'-oligoadenylate  synthetase  like  
RSAD2  radical  S-adenosyl  methionine  domain  containing  2  
PRG4  proteoglycan  4  
IFI44L  interferon  induced  protein  44  like  
PRSS35  serine  protease  35  
CMPK2  cytidine/uridine  monophosphate  kinase  2  
MX1  MX  dynamin  like  GTPase  1  
IFIT1  interferon  induced  protein  with  tetratricopeptide  repeats  1  
OAS1  2'-5'-oligoadenylate  synthetase  1  
ISG15  ISG15  ubiquitin  like  modifier  
MX2  MX  dynamin  like  GTPase  2  
IFI6  interferon  alpha  inducible  protein  6  
FYB1  FYN  binding  protein  1  
CRYGS  crystallin  gamma  S  
IFI27  interferon  alpha  inducible  protein  27  
IFIT3  interferon  induced  protein  with  tetratricopeptide  repeats  3  
BST2  bone  marrow  stromal  cell  antigen  2  
IFIH1  interferon  induced  with  helicase  C  domain  1  
OAS2  2'-5'-oligoadenylate  synthetase  2  
IFITM1  interferon  induced  transmembrane  protein  1  
USP18  ubiquitin  specific  peptidase  18  
HERC5  HECT  and  RLD  domain  containing  E3  ubiquitin  protein  ligase  5  
RTP4  receptor  transporter  protein  4  
CCDC33  coiled-coil  domain  containing  33  
KCNK3  potassium  two  pore  domain  channel  subfamily  K  member  3  
C3orf80  chromosome  3  open  reading  frame  80  
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KIT  KIT  proto-oncogene,  receptor  tyrosine  kinase  
PTPRE  protein  tyrosine  phosphatase  receptor  type  E  
LDLRAD4  low  density  lipoprotein  receptor  class  A  domain  containing  4  
MGARP  mitochondria  localized  glutamic  acid  rich  protein  
OAS3  2'-5'-oligoadenylate  synthetase  3  
SLC16A6  solute  carrier  family  16  member  6  
ALDH1A1  aldehyde  dehydrogenase  1  family  member  A1  
RNF128  ring  finger  protein  128  
CCL3L1  C-C  motif  chemokine  ligand  3  like  1  
ADGRG1  adhesion  G  protein-coupled  receptor  G1  
LGALS9  galectin  9  
TSPAN15  tetraspanin  15  
MMP1  matrix  metallopeptidase  1  
AQP3  aquaporin  3  (Gill  blood  group)  
GPR68  G  protein-coupled  receptor  68  
PTHLH  parathyroid  hormone  like  hormone  
XAF1  XIAP  associated  factor  1  
MYOZ1  myozenin  1  
HERC6  HECT  and  RLD  domain  containing  E3  ubiquitin  protein  ligase  family  member  6  
IRF7  interferon  regulatory  factor  7  
RASL11B  RAS  like  family  11  member  B  
PKIB  cAMP-dependent  protein  kinase  inhibitor  beta  
LCE1C  late  cornified  envelope  1C  
CD70  CD70  molecule  
HS3ST2  heparan  sulfate-glucosamine  3-sulfotransferase  2  
RSPO2  R-spondin  2  
TNFSF11  TNF  superfamily  member  11  
LYPD6B  LY6/PLAUR  domain  containing  6B  
LAMC3  laminin  subunit  gamma  3  
MGP  matrix  Gla  protein  
SPP1  secreted  phosphoprotein  1  
NEFL  neurofilament  light  
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CXCL11  C-X-C  motif  chemokine  ligand  11  
PI16  peptidase  inhibitor  16  
NOX4  NADPH  oxidase  4  
F2RL1  F2R  like  trypsin  receptor  1  
PLXNA4  plexin  A4  
NPPC  natriuretic  peptide  C  
CCL5  C-C  motif  chemokine  ligand  5  
PLXDC1  plexin  domain  containing  1  
CXADR  CXADR  Ig-like  cell  adhesion  molecule  
CXCL1  C-X-C  motif  chemokine  ligand  1  
LRFN5  leucine  rich  repeat  and  fibronectin  type  III  domain  containing  5  
LCE2A late  cornified  envelope  2A  
GRIN2A  glutamate  ionotropic  receptor  NMDA  type  subunit  2A  
EPHB1  EPH  receptor  B1  
EFEMP1  EGF  containing  fibulin  extracellular  matrix  protein  1 
MT1G  metallothionein  1G  
LYPD3  LY6/PLAUR  domain  containing  3  
GPRC5A  G  protein-coupled  receptor  class  C  group  5  member  A  
CCL2  C-C  motif  chemokine  ligand  2  
SEMA7A  semaphorin  7A  (John  Milton  Hagen  blood  group)  
PIP  prolactin  induced  protein 
CXCL6  C-X-C  motif  chemokine  ligand  6  
TAGLN3  transgelin  3  
CST1  cystatin  SN  
APOE  apolipoprotein  E  
IL1B  interleukin  1  beta  
SYTL5  synaptotagmin  like  5  
ATP6V0D2  ATPase  H+  transporting  V0  subunit  d2  
DPT  dermatopontin 
PTGDR  prostaglandin  D2  receptor  
NFATC2  nuclear  factor  of  activated  T  cells  2  
IFITM10  interferon  induced  transmembrane  protein  10  
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SLITRK6  SLIT  and  NTRK  like  family  member  6  
LCE3D late  cornified  envelope  3D  
CHODL  chondrolectin  
PLD5  phospholipase  D  family  member  5  
C11orf96  chromosome  11  open  reading  frame  96  
IVL  involucrin  
CLCA2  chloride  channel  accessory  2  
IL1A  interleukin  1  alpha  
RANBP3L  RAN  binding  protein  3  like  
RRAD  RRAD,  Ras  related  glycolysis  inhibitor  and  calcium  channel  regulator  
RASD2  RASD  family  member  2  
ANGPTL1  angiopoietin  like  1  
SHISAL2B  shisa  like  2B  
PRDM1  PR/SET  domain  1  
KYNU  kynureninase  
USP53  ubiquitin  specific  peptidase  53  
GAB3  GRB2  associated  binding  protein  3  
RSPO3  R-spondin  3  
DDX58  DExD/H-box  helicase  58  
IFIT2  interferon  induced  protein  with  tetratricopeptide  repeats  2  
ICOSLG  inducible  T  cell  costimulator  ligand 
NKX2-2  NK2  homeobox  2  
PIEZO2  piezo  type  mechanosensitive  ion  channel  component  2  
MMP3  matrix  metallopeptidase  3  
IGFL3  IGF  like  family  member  3  
TBX21  T-box  transcription  factor  21  
PMCH  pro-melanin  concentrating  hormone  
RARRES2  retinoic  acid  receptor  responder  2  
LCE2C  late  cornified  envelope  2C  
EGR2  early  growth  response  2  
CSF2  colony  stimulating  factor  2 
TTR  transthyretin  
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STATH  statherin  
MYOC  myocilin  
CCL8  C-C  motif  chemokine  ligand  8  
CORIN corin,  serine  peptidase  
HS6ST3  heparan  sulfate  6-O-sulfotransferase  3  
PTPRR  protein  tyrosine  phosphatase  receptor  type  R  
NR0B1  nuclear  receptor  subfamily  0  group  B  member  1  
SCUBE3  signal  peptide,  CUB  domain  and  EGF  like  domain  containing  3  
BCAN  brevican  
SCG5  secretogranin  V  
OLFML1  olfactomedin  like  1  
GRB14  growth  factor  receptor  bound  protein  14  
PDE6A phosphodiesterase  6A  
ADH1B  alcohol  dehydrogenase  1B  (class  I),  beta  polypeptide  
RIPK4  receptor  interacting  serine/threonine  kinase  4  
COL15A1  collagen  type  XV  alpha  1  chain  
DHRS2  dehydrogenase/reductase  2  
PCP4  Purkinje  cell  protein  4  
KRT14  keratin  14  
CHI3L1  chitinase  3  like  1  
ABI3  ABI  family  member  3  
GUCY1A2  guanylate  cyclase  1  soluble  subunit  alpha  2  
FRMD3  FERM  domain  containing  3  
BMF  Bcl2  modifying  factor  
MEGF10  multiple  EGF  like  domains  10  
TSGA10IP  testis  specific  10  interacting  protein  
NTSR1  neurotensin  receptor  1  
SAMD11  sterile  alpha  motif  domain  containing  11  
KISS1  KiSS-1  metastasis  suppressor  
TMEM244  transmembrane  protein  244  
HTR7  5-hydroxytryptamine  receptor  7 
MEST  mesoderm  specific  transcript  
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ITGA10  integrin  subunit  alpha  10  
WNT16  Wnt  family  member  16  
CGA  glycoprotein  hormones,  alpha  polypeptide  
DRAXIN  dorsal  inhibitory  axon  guidance  protein  
PAPPA2  pappalysin  2  
DLX2  distal-less  homeobox  2  
C19orf33  chromosome  19  open  reading  frame  33  
ITGB6  integrin  subunit  beta  6  
SNTG1 syntrophin  gamma  1  
USP44  ubiquitin  specific  peptidase  44  
WNT7B  Wnt  family  member  7B  
ODAPH  odontogenesis  associated  phosphoprotein  
TINCR  TINCR  ubiquitin  domain  containing  
ST8SIA5  ST8  alpha-N-acetyl-neuraminide  alpha-2,8-sialyltransferase  5  
SNAP25  synaptosome  associated  protein  25  
CPA4  carboxypeptidase  A4  
SOX5  SRY-box  transcription  factor  5  
ISLR2  immunoglobulin  superfamily  containing  leucine  rich  repeat  2  
TNFAIP6  TNF  alpha  induced  protein  6  
TMEM132B  transmembrane  protein  132B  
PLA1A phospholipase  A1  member  A  
KRT81  keratin  81  
PLAAT4  phospholipase  A  and  acyltransferase  4  
BAALC  BAALC  binder  of  MAP3K1  and  KLF4  
LCE1F  late  cornified  envelope  1F  
SALL1  spalt  like  transcription  factor  1  
SYT1  synaptotagmin  1  
ANKRD33B  ankyrin  repeat  domain  33B  
CHRNA9  cholinergic  receptor  nicotinic  alpha  9  subunit  
HMOX1  heme  oxygenase  1  
UNC5B  unc-5  netrin  receptor  B 
PGF  placental  growth  factor  
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PTPRZ1  protein  tyrosine  phosphatase  receptor  type  Z1  
KRTAP4-8  keratin  associated  protein  4-8  
CRHBP  corticotropin  releasing  hormone  binding  protein  
CCL20  C-C  motif  chemokine  ligand  20  
S100B  S100  calcium  binding  protein  B  
LYPD1  LY6/PLAUR  domain  containing  1  
CLDN14  claudin  14  
APOD  apolipoprotein  D  
GALNT15  polypeptide  N-acetylgalactosaminyltransferase  15  
FABP4  fatty  acid  binding  protein  4  
CDH20 cadherin  20  
GASK1B  golgi  associated  kinase  1B  
VSIR  V-set  immunoregulatory  receptor  
HEY2  hes  related  family  bHLH  transcription  factor  with  YRPW  motif  2 
LRRC4  leucine  rich  repeat  containing  4  
AQP1  aquaporin  1  (Colton  blood  group)  
EXPH5 exophilin  5  
MSMP  microseminoprotein,  prostate  associated  
HRK  harakiri,  BCL2  interacting  protein  
LRRN1  leucine  rich  repeat  neuronal  1  
SERPINB9 serpin  family  B  member  9  
HTR2A  5-hydroxytryptamine  receptor  2A  
SMOC1  SPARC  related  modular  calcium  binding  1  
ANO1  anoctamin  1  
IL18  interleukin  18  
APCDD1  APC  down-regulated  1  
PRELP  proline  and  arginine  rich  end  leucine  rich  repeat  protein  
SCG2  secretogranin  II  
WNT11  Wnt  family  member  11  
HES1  hes  family  bHLH  transcription  factor  1  
GABRB2  gamma-aminobutyric  acid  type  A  receptor  subunit  beta2  
CXCL14  C-X-C  motif  chemokine  ligand  14  
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SFRP4  secreted  frizzled  related  protein  4  
BACH2  BTB  domain  and  CNC  homolog  2  
DMKN  dermokine  
CCK  cholecystokinin  
G0S2  G0/G1  switch  2  
ANKRD30B  ankyrin  repeat  domain  30B  
ZNF556  zinc  finger  protein  556  
HAPLN1  hyaluronan  and  proteoglycan  link  protein  1  
FABP3  fatty  acid  binding  protein  3  
KCNN2  potassium  calcium-activated  channel  subfamily  N  member  2  
PPL  periplakin  
GDF5  growth  differentiation  factor  5 
BEX5  brain  expressed  X-linked  5  
TINAGL1  tubulointerstitial  nephritis  antigen  like  1  
STEAP4  STEAP4  metalloreductase  
COMP  cartilage  oligomeric  matrix  protein  
PTGIS  prostaglandin  I2  synthase  
CFD  complement  factor  D  
ADAMTSL4  ADAMTS  like  4  
  
Appendix  Figure  1.  Plots  comparing  log2  expression  profiles  of  differential  expressed  
genes  between  gene  knockout  groups  compared  to  non-targeting  control  groups.   
1)  ABCA1,  2)  ABO,  3)  ADAMTS6,  4)  AFAP1,  5)  ALDH9A1,  6)  ANAPC1,  7)  ANGPT1,  8)  
ANGPT2,  9)  ANGPTL2,  10)  ANKH,  11)  ANTXR1,  12)  ARHGEF12,  13)  ATXN2,  14)  BCAS3,  
15)  CAPZA1,  16)  CAV1,  17)  CAV2,  18)  CDH11,  19)  COL24A1,  20)  CTTNBP2,  21)  CYP1B1,  
22)  DGKG,  23)  EFEMP1,  24)  EMCN,  25)  EMID1,  26)  ETS1,  27)  FBXO32,  28)  FER,  29)  
FERMT2,  30)  FMNL2,  31)  FNDC3B,  32)  FOXC1,  33)  GAS7,  34)  GMDS,  35)  GNB1L,  36)  
KALRN,  37)  KREMEN1,  38)  LMO7,  39)  LMX1B,  40)  LTBP2,  41)  ME3,  42)  MECOM,  43)  
MYOC,  44)  MYOF,  45)  PARD3B,  46)  PDE7B,  47)  PKHD1,  48)  PLEKHA7,  49)  PRSS23,  50)  
PTPRJ,  51)  RALGPS1,  52)  RUNX2,  53)  SPTBN1,  54)  TEK,  55)  TES,  56)  TEX41,  57)  TIMP3,  
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